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Since 2001, SIRUS has been the Norwegian Fo-
cal Point for the European Monitoring Centre 
for Drugs and Drug Addiction - EMCDDA. All 
member countries submit an annual national re-
port and, in addition, a number of standardised 
tables, mainly epidemiological data. They have 
been submitted separately to the EMCDDA.
As in previous years, this 9th national report on 
the drug situation in Norway has been drawn up 
in accordance with the reporting guidelines com-
mon to all 30 member states in the EMCDDA. 
Since the report is intended to be brief and to pri-
marily cover important development trends, it 
may appear fragmentary. Little of the information 
provided in last year’s report has been repeated. 
References are included instead. However, we 
hope that the content will be prove useful to rea-
ders who wish to familiarise themselves with the 
drugs situation in Norway. SIRUS wishes to 
 express its gratitude to all that helped in the pre-
paration of the report. Our thanks go in particular 
to the co-authors who have made textual contri-
butions and to the author of the selected topic. 
Oslo, December 2009 
Odd Hordvin
Head of Focal Point
Forord 
SIRUS har fra 2001 vært det norske kontaktpunktet i 
EU’s narkotikaovervåkingsbyrå - EMCDDA. Hvert 
år leverer alle medlemslandene en nasjonal rapport 
og en rekke standardiserte tabeller, mest innen epi-
demiologi.  Disse er blitt sendt EMCDDA separat.
Som i tidligere år er denne niende nasjonale rap-
porten om narkotikasituasjonen i Norge blitt ut-
arbeidet etter retningslinjer felles for alle 30 
medlemslandene i EMCDDA. Siden rapporten 
skal være kortfattet og mest omhandle sentrale 
utviklingstrekk, kan den oppfattes som fragmen-
tarisk. Informasjon som ble gitt i fjorårets rap-
port er i liten grad blitt gjentatt, i stedet er det 
gjort henvisninger. Rapporten tar ellers ikke mål 
av seg til å gi et fullstendig bilde av det som skjer 
på rusmiddelfeltet i Norge. Vi håper likevel at 
innholdet kan være av interesse for de som vil 
sette seg inn i forhold på narkotikaområdet. Rap-
porten er på engelsk, men med et sammendrag 
også på norsk. To spesialtemaer er nye av året, 
om cannabismarkedet og om problembruk av 
amfetamin og metamfetamin. De fleste dataene 
er fra 2008, mens teksten er oppdatert frem til 
høsten 2009. SIRUS ønsker å takke alle som har 
 bidratt. Vår takk går spesielt til medforfatterne 
og til forfatterne av spesialtemaene. 
Oslo, desember 2009 
Odd Hordvin
Leder av det norske kontaktpunktet
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dency, thus resulting in greater social inclusion 
and better life coping.
In connection with the Directorate of Health’s 
grant schemes, great emphasis is placed on eva-
luating the measures and earmarking funds for 
this purpose. The goal is to help to improve qua-
lity and to support knowledge-based strategies 
and measures by ensuring continuity and local 
support. 
Drug use among young people
The latest ESPAD survey among 15 to 16-year-
old school students was carried out in 2007. The 
figures showed stability and, in part, a decline in 
relation to previous surveys. The decline is most 
pronounced in the use of cannabis. In 2007, 
around six per cent stated that they had ever 
used cannabis, while the corresponding figure 
for 2003 was nine per cent and, in 1999, 12 per 
cent. There were no significant changes for use 
during the last 30 days, however, which has been 
around two to three per cent in the last two sur-
veys. The decline in cannabis use also reflects the 
tendency in Europe as a whole.
As regards the use of illegal substances other 
than cannabis, there have been minor changes in 
lifetime prevalence among young people under 
the age of 20. On the other hand, the proportion 
of young adults aged 21 to 30 who have ever used 
cocaine has tripled, from three per cent in 1998 
to nine per cent in 2006. The proportion repor-
ting that they have ever used amphetamine has 
increased from five per cent to ten per cent du-
ring the same period. However, the proportion 
of young adults who have used amphetamine or 
cocaine during the last six months has remained 
stable at around two per cent.
Main report –Part A
National policies and context
On 15 June 2009, the Norwegian parliament de-
cided to make the temporary Act relating to in-
jection rooms permanent. The injection room 
scheme will serve as a supplement in an overall 
chain of measures targeting those with major 
health problems who have difficulty quitting 
their drug use. Based on local needs, the indi-
vidual municipalities can decide whether they 
wish to establish an injection room scheme. The 
legislative amendments with pertaining regula-
tions enter into force on 17 December 2009.
The Government’s action plan for the drugs and 
alcohol field was presented to the Storting in Oc-
tober 2007. It includes goals and measures for 
prevention, treatment and rehabilitation and en-
tails a gradual escalation of funding in the period 
up until 2010. The Directorate of Health is re-
sponsible for implementing large parts of the 
drugs and alcohol policy. Moreover, it shall en-
sure that an overview of the drugs and alcohol 
situation is available at the regional and local le-
vel, and it will publish an annual status report. 
According to the Directorate of Health, 115 of 
the Action Plan’s 147 measures had been initia-
ted at the end of 2008. Many of the measures are 
evaluated separately, and a comprehensive revi-
ew of experience from the plan will be carried 
out.
A total of 19 drugs and alcohol advisers have 
been appointed by the 18 county governor offi-
ces. They will contribute to the implementation 
of the Action Plan in the municipalities. A three-
year trial has started involving coordinating re-
presentatives in 30 selected municipalities. The 
aim of having such representatives is to help to 
ensure more coherent and individually-adapted 
services for people with drug or alcohol depen-
Summary –main findings 
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There seems to be a clear connection between 
the use of cannabis and central stimulants among 
both youth and young adults. The proportion 
who had also used central stimulants increased 
in step with the number of times cannabis had 
been used. The majority of those who had used 
cannabis more than 51 times had also tried amp-
hetamine or cocaine. The vast majority of those 
who stated that they had used central stimulants 
have previously used hash. 
Among problem drug users
The number of injecting drug users in 2007 can 
be estimated to be between 8,600 and 12,600. 
This includes all injecting use. Heroin is the drug 
most commonly injected, but amphetamine is 
also injected. 
In a new survey covering the years 2000 to 2008 
it has been estimated how many people have 
used heroin in Norway, including those who 
have only smoked it. To be able to estimate the 
total consumption, the users were divided into 
categories according to frequency of use and how 
the drug is taken. Based on different methods, it 
is estimated that between 6,600 and 12,300 had 
used heroin regularly in 2008, a considerable re-
duction in relation to 2000 when the estimate 
was 9,550 to 17,750.
Treatment
In-patient treatment capacity has been stable 
since 2004, with a slight increase in the number 
of detoxification places and minor changes in the 
breakdown between short-term and long-term 
treatment. More people receive outpatient treat-
ment, and there has been a significant increase in 
the number of people receiving substitution 
treatment. Figures from the Norwegian Patient 
Register show an increase of 16 per cent in new 
referrals to interdisciplinary specialist treatment 
from 2007 to 2008.
The national client mapping survey for 2008 
shows that, except for alcohol, which still acco-
unts for nearly half of the registrations on admis-
sion to treatment facilities and care services, he-
roin is most often reported as the most used 
intoxicant (18%). The percentage reporting he-
roin is in strong decline, however. In 2006, it was 
24 per cent, while in the early 2000s it was around 
35 per cent. The gender differences have evened 
out; the proportion of women reporting heroin 
as the most used intoxicant was much higher a 
few years ago. There was no change for cannabis 
and central stimulants as the most used intoxi-
cants from 2006 to 2008. The gender differences 
are also stable for both substance groups.
Health correlates and consequences
The incidence of HIV among injecting drug us-
ers in the group has remained at a stable, low 
level, with about 10 to 15 cases reported per year. 
The reason for this is not entirely clear, but a high 
level of testing, great openness regarding HIV 
status within the user milieus, combined with a 
strong fear of being infected and strong internal 
justice in the milieu, are assumed to be impor-
tant factors.
Both the figures from Statistics Norway and the 
National Crime Investigation Service figures ap-
pear to indicate that a certain stabilisation of the 
number of drug-related deaths has occurred in 
the last 5-6 year period. The number of overdose 
deaths per year remains high, however. Even 
though the number of clients in medication as-
sisted treatment has increased strongly during 
the same period, this has not led to a marked de-
cline in the number of deaths.
Drug crimes
In 2008, the police registered 37,531 drug offenc-
es, one of the lowest figures in the last ten years. 
The decline from 2007 was somewhat greater for 
drug offences that are regulated by the Act relat-
ing to medicines than for more serious drug of-
fences regulated by the General Civil Penal Code. 
In 2007, which is the last year that such informa-
tion is available, the total number of convictions 
for drug offences was 14,430. Only 1,220 convic-
tions resulted in unconditional prison sentences. 
In 2008, the number of sentences started as an 
alternative to prison showed a marked increase 
on previous years.
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proportion was seized in 2007, less than three 
per cent.
In 2008, 19,619 drug cases and 23,835 seizures 
were registered. This represents a decline from 
2007 of four and three per cent, respectively. 
However, there are big differences between the 
different types of drugs. While there were only 
small changes in the number of seizures of the 
most common drugs in 2008, the changes in 
terms of quantity were substantial.
While only 8.0 kg of heroin was seized in 2007, a 
number of medium-sized seizures were again 
made in 2008, amounting to a total of 55.2 kg. 
Seizures of heroin in 2008 only accounted for ap-
prox. five per cent of the total number of drug 
seizures in Norway. By comparison, this propor-
tion was as high as 20 per cent in 1998.
The largest ever seizure of amphetamine in Nor-
way, 112.3 kg, was made in 2008. Based on the 
number of seizures and verified analyses, the pro-
portion of methamphetamine once again increas-
ed significantly in relation to amphetamine. 
The amount of cannabis seized in 2008 was 1,732 
kg, which breaks down into about 71 per cent of 
cannabis resin, nine per cent of herbal cannabis 
and 20 per cent of cannabis plants. One seizure of 
401 kg of cannabis resin dominated in 2008. Many 
”cannabis plantations”, some of them large, were 
also uncovered in the first six months of 2008.
In 2008, less cocaine was seized than in 2007. 
Cocaine was seized in 26 of the country’s 27 po-
lice districts, but there are relatively big differen-
ces between the districts. In Oslo, the number of 
seizures declined by 17 per cent, while Bergen, 
the second largest city, registered an increase of 
63 per cent.
Drugs market, availability and supply 
The estimated consumption of heroin in Norway 
during the course of one year has been calculated 
for the first time. According to the survey, the 
quantity of heroin used in 2006 was estimated to 
be approximately 1,445 kilos, while consumption 
in the period 2000 to 2002 was estimated to be 
just over 2,000 kilos. The decline is mainly due to 
a decline in the number of problem users. The 
estimate for 2006 will probably also apply to 2007 
and 2008. 
Heroin sold in Norway mainly comes from Afg-
hanistan through Turkey via two northerly ro-
utes through Bulgaria/Romania–Ukraine/Rus-
sia, and then on to Poland /Lithuania. Two 
southerly routes go through Greece/the Balkans 
to the Netherlands/Germany.
According to the customs service, most of the 
amphetamine and methamphetamine on the 
Norwegian market comes from illegal laborato-
ries in the Netherlands, Poland and Lithuania. 
Lithuanian criminals have had a dominant role 
for several years as suppliers of synthetic drugs 
to Norway, and the proportion of amphetamine 
seized from Lithuania is increasing. However, 
the largest quantities of amphetamine seized now 
come from the Netherlands and Poland. The 
main routes go through Germany and Denmark 
via Sweden.
Cannabis seized in Norway mainly comes from 
Morocco via the Netherlands, while cocaine, as 
before, comes from South America to Africa and 
Spain and from there to the Netherlands and 
Germany before continuing up through Den-
mark to Norway.
Seizures
For the period 2000 to 2008, SIRUS has estimat-
ed that the total seizures by the police and the 
customs service amount to an average of only 
four per cent of the assumed total consumption 
of heroin in Norway per year. The highest pro-
portion of seizures took place in 2004, eight per 
cent of annual consumption, while the lowest 
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Problem amphetamine and  
methamphetamine use
The main findings in the data collated indicate 
that there has been an increase in the use of am-
phetamines in Norway for many years and that 
this increase has mostly concerned the use of 
methamphetamine. This represents something 
of a contrast to previous reports that indicate lit-
tle use of methamphetamine in our part of Eu-
rope, while it confirms previous reports from 
EMCDDA indicating that Norway is the country 
in Europe with the quantitatively largest and 
highest number of seizures, and where the prob-
lems associated with methamphetamine can also 
be substantial.
The most remarkable finding in the survey pre-
sented is that most of the amphetamine used now 
appears to be methamphetamine. The increase in 
the proportion of methamphetamine has been a 
linear trend over many years in all the available 
data sources. As regards seizures, 2009 appears to 
be the year when the number of methampheta-
mine seizures exceeds that of amphetamine.
There is reason to believe that the trend has more 
to do with supply. New drug trading patterns 
have developed in step with the liberalisation of 
border controls in Europe, and there is reason to 
believe that the most important explanation for 
the shift from amphetamine to methampheta-
mine as the predominant substance in Norway is 
new producers and importers in the market, pos-
sibly production in the Baltic countries.
The combination of users not knowing whether 
they are using amphetamine or methampheta-
mine, the fact that the use of amphetamines is 
increasing and that methamphetamine has be-
come the predominant amphetamine on the 
Norwegian market means that there is a clear 
danger that we will see more negative consequ-
ences of such use in Norway than in many other 
countries. The available road traffic data and data 
from psychiatric services are two examples that 
point in that direction. 
Selected issues –Part B
Cannabis market 
The police often claim that the cannabis market 
has been dominated by a few major players who 
have been active for several decades. It is a well-
known fact that these persons have connections 
with established organised criminal gangs that 
are involved in several types of crimes. 
The market seems to be highly flexible and has 
ties to several quite distinct milieus. We have a 
fairly good overview of street-level sales. Know-
ledge about smugglers and couriers is also relati-
vely extensive. On the other hand, we know little 
about the so-called ringleaders and wholesale de-
alers. The question is whether there are any clear 
ringleaders. There are many indications that there 
are few links in the chain between importation 
and the direct sale of hash to users. Price estimates 
suggest that sellers buy from persons who 
themselves have bought the drug from importers, 
or that there is one more link in the chain. 
The flexibility in the importation of cannabis 
means that the market is open to many players. It 
is highly adaptable and will therefore be relati-
vely unaffected if the police or customs service 
manages to catch one or more major players. In 
many cases, hash smuggling is combined with 
the smuggling of pills, amphetamine and ecstasy. 
On the other hand, there seems to be almost no 
connection whatsoever between those who are 
involved with heroin and those involved with 
hash. People who smuggle spirits very seldom 
have anything to do with hash. 
The cannabis market is often linked to particular 
ethnic groups. It is assumed that Moroccans have 
come to play an important role in several Euro-
pean countries. In Norway, importation and dis-
tribution seems to be a largely multi-ethnic busi-
ness. It is common to see teams of smugglers 
composed of persons from Norwegian, Asian 
and African backgrounds. Street-level sales have 
in recent years largely been dominated by groups 
of people from immigrant backgrounds. 

PART A 
New Developments and Trends
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1.2 Institutional framework, 
strategies and policies 
The Minister of Health and Care Services has 
overall responsibility for drugs and alcohol poli-
cy in Norway and for coordinating efforts in the 
field. Drugs and alcohol policy involves several 
different sectors and requires cooperation and 
coordination across ministry and agency bound-
aries. Moreover, there is a tradition in Norway 
for pursuing a holistic alcohol and drugs policy, 
including integrated action plans for the whole 
field.
Responsibility for interdisciplinary specialist tre-
atment has been assigned to the four regional 
health authorities. Norwegian drugs and alcohol 
policy is decentralised to a great extent, and chief 
responsibility for prevention, rehabilitation and 
reintegration of drug and alcohol users in the lo-
cal community has been delegated to the muni-
cipalities. 
1.2.1 Norwegian National Action Plan on 
Alcohol and Drugs
The Government’s escalation plan for the drugs 
and alcohol field, hereinafter called the Action 
Plan, was presented to the Storting in October 
2007. It includes goals and measures for preven-
tion, treatment and rehabilitation and entails a 
gradual escalation of funding in the period up 
until 2010. 
The Action Plan deals with both alcohol and 
drugs policy and national and international me-
asures, and it is based on a policy with a clear 
public health perspective. The aim is to raise pro-
fessional standards through research and by im-
proving competence and quality. As regards ser-
vices, the principle is that the ordinary services 
should also be available to people with drug or 
1.1 Legal framework 
On 15 June 2009, the Norwegian parliament - 
the Storting decided to make the temporary Act 
relating to injection rooms (see NR1 2008 Chap-
ter 1.1) permanent. Making the act permanent 
means that municipalities that wish to establish 
injection rooms have a legal basis for doing so. 
The injection room scheme will not replace mea-
sures focusing on prevention and rehabilitation, 
but will serve as a supplement in an overall chain 
of measures targeting those with major health 
problems who have difficulty quitting their drug 
use. Based on local needs, the individual munici-
palities can decide whether they wish to establish 
an injection room scheme. The legislative amend-
ments with pertaining regulations enter into 
force on 17 December 2009.
On 15 June 2009, the Oldelsting adopted an Act 
amending the Health Personnel Act. The amend-
ment requires health personnel to help meet the 
need for information and necessary follow-up 
that minor children of parents with mental ill-
nesses, drug/alcohol dependency or somatic ill-
ness or injury may have as a result of their pa-
rents’ condition. The Ministry of Health and 
Care Services can issue regulations that specify 
the duties of health personnel pursuant to this 
provision.
1 NR-National report
1.  Drug policy: legislation, strategies and 
economic analysis
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The Directorate of Health is responsible for im-
plementing large parts of the drugs and alcohol 
policy. The Directorate has wide-ranging respon-
sibility for the Action Plan, and it has chief re-
sponsibility for 58 of the 147 individual measures 
in the plan. Moreover, it shall ensure that an 
overview of the drugs and alcohol situation is av-
ailable at the regional and local level, and it will 
publish an annual status report. 
During the period 2008 to 2009, a total of 19 
drugs and alcohol advisers have been appointed 
by the 18 county governor offices. They will con-
tribute to the implementation of the Action Plan 
in the municipalities. The drugs and alcohol ad-
visers’ responsibilities include the administration 
of grants, competence-building measures, advice 
and guidance, follow-up, regional meetings/ 
forums and the establishment of learning 
networks. Among other things, the county go-
vernor offices will help to ensure that more mu-
nicipalities can avail themselves of government 
grant schemes aimed at providing users with in-
dividual follow-up and holistic services, and help 
to increase the proportion of users with indivi-
dual plans. 
The county governors are also responsible for 
following-up a trial scheme involving coordina-
ting representatives (see Chapter 8.1.1). The co-
unty governors will also facilitate competence-
building measures in the municipalities and 
administer funds for further education in the 
drugs and alcohol field for health and social ser-
vice personnel and correctional service staff. In 
collaboration with the seven regional drugs and 
alcohol competence centres, regional drugs and 
alcohol forums and meetings will be organised. 
The county governors will also help to ensure 
that the municipalities practise user participati-
on to a greater extent and that they offer services 
to family members of people with drug or alco-
hol problems. 
Evaluation of policies and strategies
The measures in the Action Plan will be specified 
in more detail during the plan period. In order to 
ensure systematic further development and im-
alcohol problems. Cooperation between the dif-
ferent bodies and administrative levels is empha-
sised, as is a user perspective.
The overriding goals are: 
•	 A	clear	public	health	perspective
•	 Better	quality	and	increased	competence
•	 More	accessible	services	and	greater	social	
inclusion
•	 Binding	cooperation
•	 Increased	user	influence	and	greater	
attention to the interests of children and 
family members.
See NR 2007 Chapter 1 for a more detailed de-
scription of the performance goals in the Action 
Plan. 
Implementation of policies and strategies
The involved ministries shall cooperate on fol-
low-up of the Action Plan. The plan assigns chief 
responsibility for each measure to a specific body, 
which will be responsible for instigating relevant 
measures and involving affected parties. Separate 
reporting procedures have been adopted for the 
Action Plan that provide an overview of the 
progress and status of each individual measure 
and of the plan as a whole. In other respects, the 
general division of responsibility in the govern-
ment administration will apply. 
The key ministries in relation to implementation 
of the Action Plan are the Ministry of Labour 
and Social Inclusion, the Ministry of Children 
and Equality, the Ministry of Justice and the Po-
lice, the Ministry of Local Government and Re-
gional Development and the Ministry of Educa-
tion and Research. The respective directorates, 
the Norwegian Institute for Alcohol and Drug 
Research, AS Vinmonopolet, the Norwegian In-
stitute of Public Health, the county governors 
and the regional drugs and alcohol competence 
centres all have important responsibilities in the 
field of drugs and alcohol policy. Good contact 
and cooperation between the different bodies is 
emphasised. 
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Interdisciplinary specialist treatment for pro-
blem drug and alcohol use, i.e. responsibility for 
detoxification, diagnosis and specialist treatment 
(including medication assisted treatment – 
MAT), is by far the biggest item of expenditure 
in the Ministry of Health and Care Services’ bud-
get for combating drug and alcohol problems. 
Since the regional health authorities are financed 
through block allocations, it is difficult to ascer-
tain precisely how much the health authorities 
allocate to interdisciplinary specialist treatment. 
Municipal services for people with drug and al-
cohol problems are usually financed by the mu-
nicipalities’ free revenues. 
Budget
The accounts for 2008 show that expenditure on 
interdisciplinary specialist treatment for alcohol 
and drug dependency amounted to EUR 331 
million2 (NOK 2.648 billion) of the regional 
health authorities’ budgets. This amount includes 
the treatment of both alcohol and drug depen-
dency and is related to specialist institutions for 
alcohol and drug dependency. The costs of treat-
ment for drug and alcohol problems at other in-
stitutions, for example in the mental health care 
services, cannot be quantified and will therefore 
come in addition.
In the national budget for 2009, an additional 
EUR 37.5 million (NOK 307 million) was alloca-
ted to the drugs and alcohol field for following 
up and implementing measures in the Action 
Plan. In 2008: EUR 15.63 million. The allocati-
ons for 2009 break down as follows:
•	 EUR	1.25	million	for	implementation	of	the	
strategy for early intervention
•	 EUR	1.0	million	for	the	preparation	of	
municipal action plans in the field of drugs 
and alcohol policy
•	 EUR	0.75	million	to	strengthen	controls	of	
licences for selling and serving alcohol
2 Conversion rate 1 EUR=NOK 8.00
plementation, regular coordination meetings are 
held between affected ministries and relevant 
subordinate agencies. The Ministry of Health 
and Care Services is in charge of coordination, 
and it is also responsible for coordinating the es-
calation plan with other plans. Status and prog-
ress will be reported annually to the Ministry of 
Health and Care Services, and this reporting 
forms the basis for an annual status report on the 
progress of the measures and the attainment of 
goals. According to the report for 2008 (the Di-
rectorate of Health, 2009), 115 (78%) of the plan’s 
147 measures had been initiated at the end of 
2008. Many of the measures are evaluated sepa-
rately, and a comprehensive review of experience 
from the plan will be carried out.
In connection with the Directorate of Health’s 
grant schemes, great emphasis is placed on eva-
luating the measures and earmarking funds for 
this purpose. The goal is to help to improve qua-
lity and to support knowledge-based strategies 
and measures by ensuring continuity and local 
support. 
1.3 Economic analysis 
1.3.1 Public expenditures
In addition to the government’s own operating 
expenses, the total allocation to the drugs and al-
cohol field consists of allocations via the Minis-
try of Health and Care Services’ budget in the 
form of grant schemes, block allocations to the 
regional health authorities and research alloca-
tions. Grants for competence and quality work, 
and to stimulate the development of methods, 
come in addition.
Important expenditures, in addition to the allo-
cations via the Ministry of Health and Social 
Care Services’ budget, include allocations to the 
customs service, the police, international pro-
jects, housing measures, employment qualifica-
tion measures and preventive efforts aimed at 
children and young people.
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and alcohol problems in order to ensure that the 
users are offered services that are coherent, com-
plex and available and that are adapted to indi-
vidual’s needs. This requires diverse and differ-
entiated services with a high degree of local 
support. The grant schemes are divided between 
two items in the national budget: 
Grants for municipal drug and alcohol measu-
res. 2009: EUR 32.2 million (NOK 258 million). 
In 2008: EUR 21.58 million. Among other things, 
these grants shall be used to strengthen personal 
guidance and individual follow-up, low-thres-
hold health services for alcoholics and drug ad-
dicts, a trial scheme for injection rooms, dental 
health services for people with drug or alcohol 
problems and street magazines such as ‘=Oslo’. 
Voluntary drug and alcohol prevention work etc. 
In 2009: EUR 16.1 million (NOK 129 million). 
In 2008: EUR 14.98 million. These grants are 
earmarked for follow-up, care and rehabilitation 
services run by voluntary organisations and pri-
vate undertakings, self-help and interest groups 
and work among family members, measures ai-
med at prostitutes and the Street Hospital in 
Oslo. 
The grant scheme Measures among children and 
young people in large towns and cities is admi-
nistered by the Ministry of Children and Equali-
ty. Grants for youth measures are distributed 
between 23 urban municipalities and, in 2009, 
they amount to EUR 2.4 million (NOK 19.2 mil-
lion). In 2008: EUR 2.1 million. These measures 
target youth groups and youth milieus that are 
deemed to be at risk. Young people from immi-
grant backgrounds face particular challenges, 
and measures that promote integration are given 
high priority. These measures will specifically 
target young people who make little use of exis-
ting cultural and leisure services and provide 
better opportunities for qualification, inclusion 
and coping. 
Grants for Voluntary work etc. are administered 
by the Directorate of Health . Funding is given in 
the form of project and operating grants for vo-
•	 EUR	0.81	million	to	strengthen	the	Research	
Council of Norway’s drug and alcohol 
research programmes
•	 EUR	62,500	to	establish	a	register	of	drug-
related deaths
•	 EUR	0.5	million	to	develop	professional	
guidelines for interdisciplinary specialist 
treatment
•	 EUR	1.0	million	(NOK	8	million)	to	
strengthen GPs’ competence in the drugs 
and alcohol field
•	 EUR	2.38	million	for	competence-building	
in municipal services
•	 EUR	7.5	million	in	increased	grants	for	the	
development of municipal services
•	 EUR	1.0	million	(NOK	8	million)	to	
strengthen the Street Hospital
•	 EUR	4.38	million	to	strengthen	Medication	
assisted treatment- MAT
•	 EUR	15	million	to	strengthen	
interdisciplinary specialist treatment
•	 EUR	0.63	million	to	establish	units	aimed	at	
mastering drugs and alcohol problems in 
prisons
•	 EUR	0.63	million	for	improved	cooperation	
and increased use of individual plans
•	 EUR	0.88	million	for	increased	user	
influence and greater attention to the 
interests of family members through 
cooperation with voluntary organisations.
Funds for the general strengthening of the mu-
nicipal sector and specialist health services come 
in addition, as well as EUR 3.75 million (NOK 
30 mill) for the Church City Mission for the es-
tablishment of immediate measures for those 
with drug or alcohol dependency who are most 
in need of help. 
Special grant schemes 
In addition to the ordinary block grant funding 
allocated to municipalities and regional health 
authorities, funds are channelled to special-pri-
ority purposes through grant schemes that are 
largely administered by the Directorate of Health 
. The purpose of the grant schemes is to promote 
professional development and the development 
of methods in the municipalities’ work on drug 
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The most important users of the centres’ services 
are employees in municipal services and the spe-
cialist health service. 
International actions
Grant for 2009 to UNODC: EUR 3 million (NOK 
29 million). Membership fees for the Council of 
Europe / the Pompidou Group, the EU’s drug 
programme and EMCDDA come in addition, as 
well as aid funds, in particular to Afghanistan, of 
which a substantial proportion is drug-related. 
1.3.2 Social costs
No adequate overview is available. The Director-
ate of Health is currently developing a statistics 
and documentation system that will provide bet-
ter information about needs and the use or re-
sources in the drugs and alcohol field and more 
health data regarding the drugs and alcohol situ-
ation in the municipalities – for example infor-
mation about efforts aimed at homeless people 
and long-term social security recipients. 
It is a challenge to quantify the status, needs, use 
of resources and service production in the drugs 
and alcohol field in the municipalities. This is 
partly due to the fact that the municipalities pri-
marily register services provided according to 
needs, not diagnoses. Several measures have 
been initiated through the Action Plan3 to pro-
vide better documentation and statistics. These 
measures will form the basis for a long-term plan 
to improve documentation. 
In 2008, for example, there were approximately 
109,000 social security recipients. It is difficult to es-
timate the number of long-term social security reci-
pients who have drug and alcohol problems, but it 
can be assumed that one in three long-term social 
security recipients are drug and/or alcohol users. 
3 The measures include: commissioning Statistics Norway (SSB) to 
carry out primary mapping of the municipal efforts in the drugs 
and alcohol field in 2006, an external assignment to map the mu-
nicipalities’ need for information in connection with their work 
in the field and to discuss the possibilities for future reporting 
and the production of statistics, good reporting procedures from 
the 202 municipalities that receive grant funding etc.
luntary organisations in the drug and alcohol 
prevention field. The purpose is to help organisa-
tions that work to reduce the consumption of 
and harm caused by drugs and alcohol to 
maintain and develop their efforts. The allocati-
on for 2009: EUR 11.5 million (NOK 92.35 mil-
lion). In 2008: EUR 11.3 million.
Research 
State funding is allocated annually to the Norwe-
gian Institute for Drug and Alcohol Research-
SIRUS and other research groups (Table 1). 
Table 1: Grants for research and dissemination in 
2009. In EUR (NOK) million. Figures for 2008 in 
italics. 
SIRUS  4.564 (36.514) 4.373
National Institute of Public Health*  1.250 (10.000) 1.250 
The Research Council of Norway. 
Programme for research and 
teaching in the drugs and alcohol 
field (including SERAF)
 3.119 (24.950) 2.312
Drugs and alcohol research 
conducted by the regional health 
authorities*
 1.875 (15.000) 1.875
Total*  10,808 (86,464) 9,810
*Approximate figure
Source: The Ministry of Health and Care Services
Regional drugs and alcohol competence 
centres 
Annual grants are paid to the seven regional 
drugs and alcohol competence centres in Nor-
way. Allocation for 2009: EUR 12.38 million 
(NOK 99 million). 2008: EUR 8.25 million.
The competence centres are an important link 
between the state and municipalities and regio-
nal health authorities in connection with the dis-
semination and implementation of research-bas-
ed knowledge and recognised methods. They 
have three main purposes:
•	 to	stimulate	the	development	of	preventive	
measures in the municipalities
•	 competence-building	in	the	municipalities	
and the specialist health service
•	 to	develop	national	areas	of	expertise.
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in the use of cannabis. In 2007, around six per 
cent (boys: 7%, girls: 5%) stated that they had 
ever used cannabis, while the corresponding fi-
gure for 2003 was nine per cent and, in 1999, 12 
per cent. There were no significant changes for 
use during the last 30 days, however, which has 
been around two to three per cent in the last two 
surveys. 
As regards the use of illegal substances other 
than cannabis, there have been minor changes in 
lifetime prevalence; it was three per cent in both 
2007 and 2003, but as high as six per cent in 
1999. 
Compared with most other European countries, 
the prevalence of illegal substances in Norway is 
low. The decline in cannabis use also reflects the 
tendency in Europe as a whole. In 2003, the av-
erage lifetime prevalence in Europe among 
young people aged 15 to 16 was 21 per cent and, 
in 2007, 19 per cent. On the other hand, it looks 
like the use of inhalants has increased somewhat 
among Norwegian school students, from five per 
cent in 2003 to seven per cent in 2007, which is 
just slightly below the European average of nine 
per cent. 
2.2.2 Drug use among youth aged 15 to 20
Data from SIRUS’s annual questionnaire survey 
among youth aged 15 to 20 in 2008 have been 
analysed (Vedøy and Skretting, 2009). Since the 
division into age groups and questions about re-
cent drug use in this survey are not in harmony 
with the division used by the EMCDDA (SIRUS: 
last six months, EMCDDA: past year and last 30 
days), the data cannot be included in standard 
tables. 
As with ESPAD, cannabis, primarily in the form 
of hash, is the drug most young people report 
2.1  Drug use in the  
general population
The most recent survey of the general popula-
tion’s drug use was carried out by SIRUS in au-
tumn 2004. The main results were discussed in 
NR 2005, Chapter 2.1). The next nationwide sur-
vey will be conducted in autumn 2009. Data and 
data analyses will be discussed in the national re-
port for 2010.
2.2  Drug use in the school and 
youth population 
2.2.1 The ESPAD survey 2007 
ESPAD4 surveys have been carried out among 15 
to 16-year-old school students every four years 
since 1995. In 2007, the survey comprised more 
than 100,000 students in 35 European countries. 
In Norway, the survey comprised all the students 
from all ten years of primary and lower second-
ary school who were registered as of March 2007. 
The survey is based on questionnaires about 
smoking, the use of alcohol, illegal substances, 
medicinal drugs and other drugs. The ESPAD 
survey is coordinated by the Swedish Council for 
Information on Alcohol and Other Drugs -CAN, 
which cooperates with the Pompidou Group, 
EMCDDA and researchers throughout Europe. 
As in previous years, SIRUS was responsible for 
the Norwegian part of the survey.
Among Norwegian school students who have 
tried illegal substances, the 2007 figures showed 
stability and, in part, a decline in relation to pre-
vious surveys. The decline is most pronounced 
4 European School Survey Project on Alcohol and Other Drugs
2.  Drug use in the general population and 
specific target groups
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sample reported having used cannabis more than 
five times during the last six months (Table 2).
Table 2: The number of times young people aged 
15-20 have used cannabis during the last six 
months, NORWAY and OSLO (2006-2008 as a whole). 
As a percentage.
Number of times during the last six months
0 1-4 5-10 11-25 26+ Total
Norway 93.8 3.3 0.7 0.5 1.7 100
Oslo 90.2 5.8 1.3 0.9 1.8 100
Source: SIRUS
Gender and age
There was little or no difference between boys 
and girls with respect to experience of using can-
nabis. The proportion of boys in Norway who 
state that they have used cannabis was slightly 
higher than for girls up until the turn of the mil-
lennium, while in recent years, the proportion of 
girls appears to have been somewhat higher. 
However, the differences were not statistically 
significant. In the special Oslo sample, the pro-
portion of boys who had used cannabis was gen-
erally higher than for girls, but on the whole the 
difference has not been statistically significant. 
In a historical perspective, the proportion stating 
that they have used cannabis ever has (naturally) 
been lower among youth aged 15 to 16 than 
among those who are slightly older, but the rela-
tionship between the different age groups has 
changed somewhat over time. For the country as 
a whole, the proportion stating that they had 
used cannabis increased for all age groups from 
1986 until the end of the 1990s (Figure 3). In the 
ensuing years, however, there appears to have 
been a decline among youth aged 15 to 16 and 17 
to 18, while the proportion of youth aged 19 to 
20 remained at the same level until 2005. In re-
cent years, the differences between the age groups 
have again decreased. In Oslo, the differences 
between the three age groups have also increased 
over time (Figure 4), but, unlike the country as a 
whole, there has been a marked decline in all age 
groups after 2000 in the proportion reporting 
that they have ever used cannabis.
having used, but this survey also shows a marked 
downward trend. At the turn of the millennium, 
less than 20 per cent nationwide and less than 30 
per cent in Oslo reported that they had every 
used hash or marijuana. Since then, there has 
been a fairly pronounced decline to just over ten 
per cent nationwide and slightly less than 20 per 
cent in Oslo (Figures 1 and 2).
Figure 1: The percentage of youth between the ages 
of 15 and 20 in Norway who state that they have taken 
cannabis: ever and during the last six months, respec-
tively, 1986 – 2008 (three-year sliding average).
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Source: SIRUS
Figure 2. The percentage of youth between the ages 
of 15 and 20 in Oslo who state that they have taken 
cannabis: ever and during the last six months, re-
spectively, 1968 – 2007 (three-year sliding average).
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Source: SIRUS
A higher proportion in Oslo than nationwide 
stated that they had used cannabis during the 
last six months. The fact that having tried can-
nabis is not the same as regular use is illustrated 
by the fact that, during the period 2006-2008 as a 
whole, only three per cent of youth aged 15 to 20 
nationwide and four per cent in the special Oslo 
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There seems to be a clear relationship between 
interrupted education and the use of cannabis 
(Figure 5). The proportion stating that they had 
used hash was many times higher among those 
who had dropped out of school without taking 
exams than among those who had remained in 
school. There may be several reasons for this ap-
parent relationship, and it may be difficult to se-
parate cause from effect. On the one hand, the 
use of drugs may have led to expulsion or to the 
student having difficulty following classes, which, 
in turn, has led to him/her dropping out. Since 
the use of cannabis is not an entirely normal 
phenomenon among youth, it is not unlikely that 
young people using drugs become more easily 
marginalised and therefore experience more 
problems at school than other young people. 
Dropping out of school may in itself affect drug 
use. The relationship between interrupted edu-
cation and the use of cannabis may be rooted in 
the same predisposing factors in terms of perso-
nality and milieu. 
Figure 5: Percentage of youth aged 15-20 stating 
that they have ever used cannabis, among those who 
have dropped out of school and those who have not 
dropped out, NORWAY (three-year sliding average).
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Source: SIRUS
The availability of cannabis
Two questions have been asked in the youth sur-
vey to shed light on the availability of cannabis:
’Have you ever been offered marijuana or hash?’
’If you wished to get hold of some marijuana or 
hash, do you believe you could obtain it in the 
space of two to three days?’
Figure 3: Percentage of the different age groups re-
porting that they have ever used cannabis, NORWAY 
(three-year sliding average).
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Figure 4: Percentage of the different age groups 
reporting that they have ever used cannabis, OSLO 
(three-year sliding average).
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What characterises people who have used 
cannabis?
The questionnaire that is used contains few ques-
tions about background factors, and nor does it 
contain questions that can shed light on respon-
dents’ mental health. There are, however, some 
clear correlations. For example, whether young 
people live with both or just one of their parents 
seems to be significant. Nationwide, during the 
period 2006 to 2008 as a whole, seven per cent of 
those who lived with both their parents stated 
that they had ever used cannabis, while the cor-
responding figure for those who lived with just 
one of their parents was 15 per cent, and 24 per 
cent for those who had a different housing situa-
tion (living with other relatives, alone, with 
friends or a partner). The same pattern is found 
in Oslo. 
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arrested for using cannabis. Again, this was pri-
marily true of those who had used cannabis a 
certain number of times. For example, less than 
ten per cent of those who stated that they had 
never used cannabis said that they had friends or 
close acquaintances who had been arrested for 
using cannabis, while the corresponding figure 
was close to 40 per cent for those who had used 
the drug between 11 and 50 times and more than 
70 per cent among those who had used cannabis 
more than 50 times (Table 3).
The use of other drugs among youth  
aged 15 to 20
The survey shows a clear relationship between 
the use of cannabis and other drugs. The propor-
tion stating that they have tried different drugs is 
clearly much higher among those who have also 
used cannabis than among those who have never 
used this drug.
After cannabis, amphetamine is the second most 
used drug by young people. The proportion in 
the 15 to 20 age group in Norway stating that 
they had ever used amphetamine increased up 
until the millennium to approximately four per 
cent, and then stagnated or declined. In Oslo 
alone, there was also an increase up until the 
millennium, when around seven per cent stated 
that they had ever used amphetamine. This was 
followed by a decline up until 2008, when around 
three per cent reported having used the drug. 
It is not specified whether the question concerns 
buying or an offer to try marijuana or hash free 
of charge. 
Naturally, most of those who say they could ob-
tain hash or marijuana have experience with the 
use of cannabis themselves. As Table 3 shows, for 
the period 2006 to 2008 seen as a whole, around 
90 per cent of those who had used the drug bet-
ween one and four times say that they could get 
hold of hash or marijuana in the space of two to 
three days. Among those who had used cannabis 
more than 11 times, the proportion was almost 
100 per cent. The corresponding figure for those 
who had not used cannabis themselves was 46 
percent nationwide and 56 per cent in Oslo 
(p<0.001).
Almost everyone who stated that they themselves 
had used cannabis reported that they also had 
friends or close acquaintances who have used the 
drug. This indicates that the use of hash or mari-
juana is linked to special milieus in these age 
groups. Regardless of whether they themselves 
have ever used cannabis, many young people in 
general state that they have friends or close ac-
quaintances who have used cannabis. For the pe-
riod 2006 to 2008 seen as a whole, this applied to 
54 percent nationwide and 67 percent in Oslo.
The survey also asked whether the respondents 
had friends or close acquaintances who had been 
Table 3: The availability of cannabis and contact with users of cannabis among youth groups aged 15-20 who 
have used cannabis a various number of times (2006-2008 as a whole), as a percentage.
Could obtain cannabis in  
two or three days
Friends or close acquaintances 
who use cannabis
Friends or close acquaintances 
who have been arrested for  
using cannabis
NORWAY OSLO NORWAY OSLO NORWAY OSLO
0 46 56 48 60 8 9
1-4 90 91 97 98 27 22
5-10 96 95 99 98 40 38
11-50 99 97 99 98 46 41
51+ 98 100 98 99 74 80
Total 52 63 54 67 12 15
Source: SIRUS
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Figure 7: Percentage of youth between the ages of 
15 and 20 who state that they have ever used vari-
ous drugs, OSLO (three-year sliding average).
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In recent years, less than six per cent in Norway 
report ever having sniffed solvents, while around 
two per cent state that they have used solvents 
during the last six months. Around four per cent 
state that they have ever used psychopharmaceu-
ticals not prescribed by a doctor.
Statistical margins of error
The figures are subject to statistical margins of 
error and must be interpreted with care. Ques-
tionnaire surveys are always susceptible to cer-
tain sources of error; for example, not everyone 
responds, some responses may contain deliber-
ate or inadvertent errors etc. Moreover, the sur-
veys referred to here target young people in gen-
eral. There is reason to believe that young people 
who regularly use drugs, either cannabis or 
stronger substances, will be underrepresented in 
the surveys. 
From the start of the survey until the mid-1990s, 
around 70 per cent responded to the question-
naires. In the period since then, this response 
rate dropped, first to approximately 50 per cent, 
then to around 40 per cent. In an attempt to in-
crease the response rate, the sample selected for 
the 2008 survey was given a choice of responding 
via traditional questionnaires or via the internet. 
However, the response rate dropped further to 
just above 30 per cent. 
Because of the declining response rate, SIRUS no 
longer considers it justifiable from a professional 
The trend for cocaine has been somewhat diffe-
rent in that there has not been a similar decline 
in recent years. Nationwide, there was an increa-
se in the 1990s from approximately 0.5 per cent 
to around two per cent at the turn of the millen-
nium. The level has remained more or less un-
changed since then. In Oslo, the proportion re-
porting that they had ever used cocaine increased 
from around one per cent in the early 1990s to 
approximately five per cent at the turn of the mil-
lennium, before levelling out. Nationwide, the 
level of cocaine use has approached the level for 
amphetamine in recent years and is now fairly 
similar. However, for the period 2004 to 2008, 
significantly higher proportions of cocaine use 
than amphetamine use were reported for Oslo. 
The proportion stating that they have used other 
drugs has generally been around 0.5 to two per 
cent (Figures 6 and 7). 
The proportion reporting use during the last six 
months is low for all drugs, except for cannabis. 
The proportion is highest for amphetamine at 
around one to two per cent. 
Figure 6: Percentage of youth between the ages of 
15 and 20 who state that they have ever used vari-
ous drugs, NORWAY (three-year sliding average).
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Nationwide, the proportion of young adults who 
have ever used cocaine has tripled from three per 
cent in 1998 to nine per cent in 2006. The pro-
portion reporting that they have ever used amp-
hetamine has increased from five per cent to ten 
per cent during the same period. In Oslo, cocai-
ne use increased from seven per cent to 14 per 
cent during the same period. The same tendency 
is found among students in Oslo. However, the 
proportion of young adults who have used amp-
hetamine or cocaine during the last six months 
has remained stable at around two per cent. 
The survey shows a clear connection between 
the use of cannabis and central stimulants among 
both youth and young adults. The proportion 
who had also used central stimulants increased 
in step with the number of times cannabis had 
been used. The majority of those who had used 
cannabis more than 51 times had also tried amp-
hetamine or cocaine. The vast majority of those 
who stated that they had used central stimulants 
have previously used hash. 
perspective to continue these traditional surveys. 
The 2008 survey was therefore the last to be car-
ried out. SIRUS has yet to decide whether other 
surveys will be initiated among young people to 
supplement the large population surveys that are 
carried out only every five years. 
2.3 Drug use among young adults
The main results from SIRUS’s questionnaire 
surveys among young adults aged 21 to 30 and 
among students were presented in NR 2007, 
Chapters 2.2.2 and 2.3.1. A recently published 
overview of amphetamine, cocaine and ecstasy 
use is based on data from these surveys, among 
others (Skretting and Vedøy, 2009). 
The survey gives a picture of what different sour-
ces tell us about the use of central stimulants in 
Norway. The overview is based on four sets of 
questionnaire surveys about the use of drugs in 
different population groups: young people bet-
ween the ages of 15 and 20, young adults between 
the ages of 21 and 30, students at the University 
of Oslo, and the adult population. In addition, it 
presents results from surveys among injecting 
drug users, problem drug and alcohol users re-
ceiving treatment, and other sources that shed 
light on the topic.
The proportion of young adults reporting that 
they have ever used amphetamine or cocaine has 
increased since the end of the 1990s, while use du-
ring the last six months has been stable. This sug-
gests that more young adults have experimented 
with amphetamine and cocaine. However, the fact 
that the figures for recent drug use are stable at 
around two percent indicates that there has not 
been an increase in regular use.
Annual report to the European Monitoring Centre for Drugs and Drug Addiction – EMCDDA 23
tion work. The guide is scheduled for completion 
in 2009 and implementation will start in 2010. 
3.1.2 Family
Parents’ role in drug prevention
Much research identifies the home and family as 
crucial arenas affecting young people’s behaviour 
as regards alcohol and drug use, although they 
are not by any means the only factors (Henriksen 
2000, Kelly et al. 2007, Saether 2007).
One important aim of the Action Plan is to raise 
the general public’s level of knowledge and to 
make people aware of the link between the age at 
which people start drinking and alcohol con-
sumption in adult life. The initial target group 
consists of young people and parents, who are to 
be given a more active role as contributors to and 
mediators in local preventative work. One im-
portant goal is to help develop good, safe local 
communities. 
Since the end of 2008, one of the regional resour-
ce centres for substance dependence problems 
has been dedicated to collecting more informa-
tion and know-how about this theme. The centre 
is in the process of drawing up a plan for this 
work with a perspective of five years.
3.1.3 Community
Action plans in the field of drugs and 
alcohol policy
The Norwegian Alcohol Act requires the munic-
ipalities to prepare local drugs and alcohol policy 
action plans. A number of other acts also assign 
tasks to the municipalities in the drugs and alco-
hol field. Based on the intention of these acts and 
local needs, the municipalities are encouraged to 
pursue a coherent drugs and alcohol policy. For 
example, licensing rules and other preventive 
measures should be seen in conjunction with re-
habilitation. Preparing a municipal drugs and al-
cohol policy action plan is a planning tool that 
The Government’s Action Plan (Chapter 1.2.1) 
includes efforts to raise professional standards in 
preventive work in Norway. One of the five main 
goals is a clear focus on public health. Informa-
tion work will be strengthened, with more tar-
geted information and more participation by 
young people and parents. Knowledge must be 
increased and attitudes changed in order to re-
duce the harmful effects. Public funding for the 
voluntary sector will continue as part of the ef-
fort to improve quality. Preventive measures will 
be coordinated and work on drug and alcohol 
prevention in the workplace will be intensified. 
The seven regional competence centres are key 
partners in coordinating and improving local 
prevention in the municipalities.
3.1 Universal prevention
3.1.1 School
For several decades, drug and alcohol prevention 
work has been based on various documents gov-
erning the school sector, such as legislation, na-
tional curricula and subject-specific curricula. A 
lot of research indicates that schools are impor-
tant arenas for preventive work and that they 
form an important basis for preventive efforts. 
However, a number of research findings over 
several years suggest that universal school-based 
measures and programmes have very limited or 
no effect in terms of reducing the use of alcohol 
and drugs and their harmful effects (Babor et al. 
2003; Foxcroft et.al. 2002; Giesbrecht 2007; Nor-
dahl et al. 2006). It is therefore necessary to nu-
ance the view that schools are good arenas for 
drug and alcohol prevention work. 
In this light, the Directorate of Health , together 
with the Directorate for Primary and Secondary 
Education, started work in 2008 on producing a 
guide to schools-based drug and alcohol preven-
3. Prevention
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programmes in lower secondary schools. The 
contents of the report will be spread among rele-
vant groups.
About khat in particular 
Khat was regulated as a narcotic substance in 
Norway in 1989, and its use and possession is 
therefore illegal pursuant to Norwegian law. The 
consumption of khat in some immigrant groups 
is alarming and a contributory factor to poor so-
cial inclusion. Measures across welfare sectors 
are therefore needed to meet this development. 
The khat problem must be seen in conjunction 
with employment and education, and close co-
operation is required between public services 
and relevant immigrant organisations. With sup-
port from the Directorate of Health, the Oslo 
drug and alcohol competence centre has pro-
duced a brochure targeting public services. It 
contains information about khat and its possible 
harmful effects. 
A brochure aimed at khat users has also been 
produced in Somali. The Oslo competence cen-
tre and the Directorate of Health have allocated 
funds for a pilot project in Oslo aimed at obtai-
ning employment for women whose husbands 
are part of a milieu in which khat is used. The 
pilot project was developed following a proposal 
from, among others, the Somali association 
SONORFUS. It was concluded in 2008, having 
achieved positive results. In 2009, the project was 
given funds for continued work and evaluation.
A large number of marginalised youth in Oslo 
from immigrant backgrounds have an income 
based on selling drugs, cannabis in particular 
(Sandberg and Pedersen 2006). There is reason 
to believe that certain groups of children and 
young people from immigrant backgrounds are 
at particular risk of developing a drug problem. 
A project supported by the Directorate of Health 
during the period 2006 to 2008 targeted young 
people from immigrant backgrounds who sell 
drugs in Oslo. The experience from this project 
will be followed up. 
should involve several municipal sectors, thereby 
ensuring coherence. The Directorate of Health, 
the regional competence centres and the county 
governors assist the municipalities in the devel-
opment and implementation of such plans.
At the end of 2007, 254 municipalities (59%) had a 
coherent drugs and alcohol policy action plan. The 
corresponding figure for 2005 was 149 (34%). 
Plan for competence-building
The Directorate of Health and the regional com-
petence centres are cooperating on a competence-
building plan. The county governors are also con-
tributing to this work. The goal is to coordinate 
and strengthen local prevention efforts in the mu-
nicipalities. Competence-building measures will 
be aimed at key personnel (administrative deci-
sion-makers, politicians, relevant sector manag-
ers, local school managers, teachers, health per-
sonnel), parents/guardians, the licensed trade, the 
police and voluntary organisations. 
3.2  Selective prevention in  
at-risk groups and settings 
3.2.1  Measures aimed at immigrant 
youth’s use of drugs and alcohol
 In 2006, the then Directorate for Health and So-
cial Affairs – now the Directorate of Health – as-
signed the Oslo Drug and Alcohol Addiction 
Service Competence Centre the task of mapping 
available knowledge about immigrant youth and 
their use and problem use of drugs and alcohol. 
The intention was to examine whether and to 
what extent youth from immigrant backgrounds 
need special measures to prevent the develop-
ment of drug and alcohol problems, and whether 
or not various immigrant youth groups need se-
parate early intervention measures in the drugs 
and alcohol field. A report was published in 2008 
(Bergengen and Larsen, 2008). See also NR 2008, 
Chapter 3.2. Based on the report, there are plans 
to produce information adapted to youth from 
different ethnic backgrounds, for example 
through adapting drug and alcohol prevention 
Annual report to the European Monitoring Centre for Drugs and Drug Addiction – EMCDDA 25
tervention projects, which can also lead to the 
development of new methods. Most of them tar-
get children and young people, who are a priori-
tised target group. Another priority group con-
sists of pregnant women. Funding has also been 
given to projects targeting arenas that are parti-
cularly well suited to early interventions, such as 
GPs, hospitals, the workplace and schools. Most 
of the projects run for several years. 
3.4  National and local media 
campaigns
There are no new media campaigns aimed at the 
use of drugs in particular. On the other hand, 
several extensive information campaigns have 
been carried out in relation to alcohol in recent 
years. Over time, these campaigns have been giv-
en a more central and visible role in preventive 
work. The main goal of preventive efforts in Nor-
way has been to reduce the harmful effects of 
drug and alcohol use on health and society by 
maintaining and increasing support among the 
general public for a restrictive alcohol policy. The 
campaigns have been one of the means to this 
end. They have targeted the general public and 
the municipalities. Information has also been 
aimed at selected groups in order to reduce prob-
lem behaviour such as harmful drinking or binge 
drinking among youth. To combat prenatal alco-
hol disorders (FASD), women of fertile age have 
been one of the target groups.
The information campaigns have been part of 
the Government’s action plan to combat drug 
and alcohol-related problems (2004-2006) and 
the escalation plan for the drugs and alcohol field 
(2008-2010). Dedicated funds have been alloca-
ted to information measures in the national bud-
get. The overall information effort has consisted 
of ‘packages’ of several measures, of which media 
and advertising campaigns for limited periods 
have been the most visible.
One example is the campaign ‘Dare to set limits’ 
(2005- ), which targets parents and young people 
with the aim of increasing parents’ awareness of 
Outreach work 
While outreach work among young people in 
high-risk milieus is part of the municipality’s gen-
eral responsibilities, it is not a statutory responsi-
bility. Topics relating to outreach work are now 
part of further education programmes at several 
university colleges. A book of methods for use in 
outreach work has also been published under the 
auspices of the Oslo Drug and Alcohol Addiction 
Service Competence Centre. In April 2008, on as-
signment for the Directorate of Health, the Oslo 
Drug and Alcohol Addition Service Competence 
Centre organised a major international confer-
ence in Oslo on ‘Outreach work’. 
3.3. Indicated prevention
3.3.1 Early intervention
On assignment for the Ministry of Health and 
Care Services, the former Directorate for Health 
and Social Affairs drew up a proposal for a na-
tional strategy (discussed in NR 2007, Chapter 
3). The proposal was presented in the report 
‘Early intervention in the drugs and alcohol field. 
Central perspectives – relevant target groups and 
arenas’, which was published in June 2007. 
As part of this national strategy, the Directorate 
of Health has prepared the guide From concern 
to action – A guide to early interventions in the 
drugs and alcohol field (in Norwegian only). The 
guide is part of a long-term programme of early 
intervention in the drugs and alcohol field. The 
aim is to increase knowledge about what public 
service managers and staff should look for in or-
der to identify a nascent drug and/or alcohol 
problem in children, young adults or older peo-
ple. The guide also provides concrete advice abo-
ut what can be done to solve a potential problem 
as early as possible. The regional competence 
centres play a key role in implementing the guide 
and in contributing to greater knowledge about 
early intervention in the public services.
During the period 2007 to 2009, the competence 
centres have been given funding by the Directo-
rate of Health to develop of a total of 25 early in-
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get as many women as possible to change their 
drinking habits when they are planning to become 
pregnant, and to abstain during the entire preg-
nancy. In addition to advertising, information 
about recent research is published in the media, 
online, at health stations, at GPs’ offices etc. Cour-
ses and conferences are being held and screening 
tools are being developed to map alcohol con-
sumption and improve cooperation between 
health authorities, child welfare services and soci-
al services in the municipalities.
their responsibility as role models and setters of 
limits. The campaign encourages parents to add-
ress the issue of alcohol consumption and to set 
limits for their own children. The dedicated web-
site http://www.settegrenser.no contains film 
clips and advice to parents. The campaign colla-
borates with schools in order to reach parents.
Norwegian authorities recommend that pregnant 
women do not drink alcohol. To inform women 
about this recommendation and the effects of al-
cohol on the foetus, an ‘Alcohol-free pregnancy’ 
campaign was run in 2007 and 2009. The goal is to 
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has been adjusted slightly in relation to previous 
estimates for the same year. This is because cal-
culations are based on a three-year sliding av-
erage and the preliminary estimate for 2006 has 
been replaced by ‘final figures’ for the same year. 
The estimate for 2007 will also be adjusted slight-
ly when the figures from the Norwegian Causes 
of Death Register for 2008 are published. The 
trend as regards the number of injecting drug 
users showed an increase until 2001. This increa-
se was followed by a decline until 2003 and a sta-
ble situation until 2008.
Table 4: Ranges for the number of injecting drug 
users in Norway 2002-2007, calculated using the 
Mortality Multiplier.* 
Year Lower limit – upper limit
2002 10,500 – 14,000
2003 9,200 – 12,800
2004 8,700 – 12,200
2005 8,900 – 12,400
2006 8,400 – 11,700
2007 8,600 – 12,000
* The figures have been rounded off
Source: SIRUS 
In accordance with previous results when other 
methods were also used, it is assumed that the 
upper limit for the number of injecting drug 
users based on the Mortality Multiplier is appro-
ximately five per cent too low. The number of in-
jecting drug users in 2007 can therefore be esti-
mated to be between 8,600 and 12,600. This 
includes all injecting use. Heroin is the drug 
most commonly injected, but amphetamine is 
also injected. In Oslo, for example, 12 per cent of 
those who obtained needles from the needle dis-
tribution service until 2004 stated that they 
mainly injected amphetamine. This percentage 
increased somewhat until 2008 (Bretteville-Jen-
sen, 2005; personal correspondence Bretteville-
Jensen, 2009). 
4.1  Prevalence and incidence 
estimates of PDU 
See data in Standard tables 07 and 085.
In the EMCDDA context, problem use is defined 
as ‘Injecting use of drugs or prolonged/regular 
use of opiates, cocaine and/or amphetamines.’ In 
Norway, we primarily have figures for the group 
that injects drugs. However, in 2009, the number 
of problem heroin users was calculated based on 
a similar definition to the one EMCDDA uses. 
Chapter 4.1.2 deals with this in more detail. 
4.1.1  Calculating the number of injecting 
drug users
For the period 2002 to 2006, the number of in-
jecting drug users in Norway was calculated us-
ing three different methods: the Mortality Multi-
plier, questionnaire surveys among the police 
and the social services in the municipalities, and 
the Multiple Indicator Method. The methods are 
described in NR 2006, Annex 1. Since 2007, it is 
only possible to use the Mortality Multiplier, as 
questionnaire surveys among the police and the 
social services in the municipalities were discon-
tinued. The Multiple Indicator Method used 
some of the data from the questionnaire surveys, 
and it was thus no longer possible to use this 
method either. 
Table 4 shows estimates for the number of injec-
ting drug users in Norway based on the Mortali-
ty Multiplier. Overdose death figures from the 
Norwegian Cause of Death Register, produced 
by Statistics Norway until 2007 and by the Natio-
nal Crime Investigation Service (Kripos) until 
2008, provide an estimate of the number of in-
jecting drug users in 2007. The estimate for 2006 
5 All standard tables referred to have been submitted to the 
EMCDDA separately 
4. Problem drug use
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le-Jensen, 2005). Based on this, a total estimated 
figure for the number of problem users of heroin 
in Norway who only smoke the drug can be cal-
culated. The estimate is only based on informa-
tion from Oslo, however. 
Table 5 shows the estimates for the number of 
problem users of heroin for the years 2000 and 
2008. The ranges have an uncertainty of 30 per 
cent. The decline from 2000 to 2008 is most pro-
bably due to a substantial increase in the availabi-
lity of substitution treatment during the period.
Table 5: Estimate of problem heroin users in 2000 
and 2008. National figures.
Problem 
users
2000 2008
Only injection 9,150 (6,400-11.900) 6,300 (4,400-8,200)
Only smoking 2,100 (1,470-2,730) 1,450 (1,000-1,900)
Both injection 
and smoking
2,400 (1,680-3,120) 1,700 (1,200-2,200)
Total number 
of problem 
users
13,650 (9,550-17,750) 9,450 (6,600-12,300)
Source: SIRUS 
4.2  Data on PDU from  
non-treatment sources
4.2.1  From the injection room  
scheme in Oslo
The injection room in Oslo opened in 2005 as a 
temporary arrangement. SIRUS evaluated the 
trial scheme in 2007 based on the two first years 
of its operation, from February 2005 to January 
2007. See National report (NR) 2008, Chapter 
7.1.1. In a new report (Skretting and Olsen, 
2009), the evaluation has been updated for the 
period July 2007 to January 2009, after the injec-
tion room moved to its new premises. See also 
Chapter 1.1. 
Number of users of the injection room 
In the first two years, 409 persons were registered 
as users, 383 of whom had actually used the ser-
vice. As of 31 January 2009, the number had tri-
pled to 1,276 registered users, 1,052 of whom 
4.1.2 Problem heroin users
The consumption of heroin in Norway has been 
estimated in a survey covering the period 2000 
to 2008 (Bretteville-Jensen and Amundsen, 
2009). As a basis for the calculations, it was esti-
mated how many people have used heroin in 
Norway, including those who have only smoked 
it. To be able to estimate the total consumption, 
the users were divided into categories according 
to frequency of use and the method of taking the 
drug: experimental users, sporadic users and 
problem users. 
By experimental users in this context is meant 
persons who take heroin once or a few times and 
then stop. Sporadic users are persons who take 
heroin more or less regularly, but not as frequ-
ently as problem users and without as many ne-
gative consequences. These users can be referred 
to as controlled users, recreational users or mo-
derate users (Stimson, Hickman, Quirk, Frischer, 
& Taylor, 1997; Stowe & Ross, 1991; Warburton, 
Turnbull, & Hough, 2005; Zinberg, 1984). Pro-
blem users are persons who use the drug more 
regularly, who experience withdrawal symptoms 
when they stop, and for whom the social, finan-
cial and health-related consequences can be gre-
at. These users can be referred to as addicts or 
heavy users. However, there is uncertainty at-
tached to the calculations. 
The size of the group of problem users of heroin 
who inject the drug is estimated using the Mor-
tality Multiplier. The size of the group of problem 
users who smoke heroin is calculated on the ba-
sis of two surveys from Oslo. One is the Client 
Survey in Oslo from 2006, which was carried out 
among users of services provided by the Alcohol 
and Drug Addiction Service in Oslo (lodging 
houses, housing services, rehabilitation etc.). On 
the basis of this material, the proportion of a 
group of problem users who only smoke heroin 
can be estimated as a percentage of those who 
inject it. The other survey is carried out among 
users of the needle distribution service in Oslo, 
which provides information about the time that 
elapsed from the first time the relevant users 
smoked the drug until they injected it (Brettevil-
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Table 6: Number of registered users by age and 
gender in the old and new injection room.
Number of registered users Average age 
Gender 
% M % F 
Old injection room 409 37 71 29 
New injection room 1,276 38 74 26 
Source: SIRUS
Frequency of use/ number of injections
The fact that the number of registered users has 
almost tripled has naturally led to an increase in 
the number of injections. In the period from July 
2007 to January 2009, a total of 27,384 injections 
were registered, which means an average of 47 
per day (based on the room being open for 580 
days). Even though this is twice as many injec-
tions as during the first two years of operation, 
when there were an average of 24 injections per 
day (17,226 in total), 47 is nonetheless a low fig-
ure compared with the number of injections in 
Oslo every day, and it may not amount to more 
than approximately one per cent of the total. 
Overdoses and overdose deaths 
During the first two years of operation, 0.61 per 
cent of the injections in the injection room end-
ed in an overdose. The proportion in the follow-
up evaluation period was more or less the same. 
Overdoses defined as sub-acute are handled by 
the staff, while ambulance personnel take care of 
resuscitation when the overdose is regarded as 
acute. It is worth noting that none of the over-
doses was fatal.
actually used the injection room during the 19 
months from July 2007 until January 2009. Be-
cause the first injection room had limited capac-
ity, it was not possible to register new users dur-
ing certain periods. After the move, new users 
could again be admitted, and the number has 
since increased steadily. In light of the fact that 
there are approximately 3,000 injecting drug us-
ers in Oslo, the number of actual users of the 
room is considered to be substantial. 
Age and gender 
The age limit for registration as a user of the in-
jection room is 18. The number of newly-regis-
tered users over the age of 40 is slightly higher in 
the new injection room than in the old one. The 
average age of those who registered in the old in-
jection room was 37, while it is 38 when those 
registered in the new room are included. As of 
January 2009, the gender distribution for regis-
tered users was 26 per cent women and 74 per-
cent men (Table 6). 
Very little is otherwise known about the users of 
the injection room with respect to their back-
ground and drug/alcohol history. This is because 
the Storting has stressed that the injection room 
scheme is intended as a low-threshold service, 
and only the gender and age of the users should 
therefore be registered.
The Drug Situation in Norway 200930
According to the status report for 2008 (the Di-
rectorate of Health, 2009), all these measures 
have been initiated. The regional health authori-
ties have been asked to increase their capacity in 
the field of interdisciplinary specialist treatment, 
with particular emphasis on acute treatment, de-
toxification and ambulant teams, as well as med-
ication assisted treatment. Everyone referred to 
interdisciplinary specialist treatment for drug 
and/or alcohol dependency will also be evaluated 
with respect to whether they need other services 
in the specialist health service. In addition, the 
efforts aimed at those with both drug or alcohol 
problems and mental health problems will be 
strengthened. Several sections in the Patients’ 
Rights Act have also been amended. 
In-patient treatment capacity has been stable 
since 2004, with a slight increase in the number 
of detoxification places and minor changes in the 
breakdown between short-term and long-term 
treatment. More people receive outpatient treat-
ment, and there has been a significant increase in 
the number of people receiving substitution tre-
atment. Figures from the Norwegian Patient Re-
gister show an increase of 16 per cent in new re-
ferrals to interdisciplinary specialist treatment 
from 2007 to 2008.
Guidelines for medication assisted  
treatment of opioid dependency 
In May 2009, the Directorate of Health and the 
Ministry of Health and Care Services distributed 
a consultative proposal for guidelines and regu-
lations relating to medication assisted treatment 
(MAT) for opioid dependency. The deadline for 
submissions was 1 September 2009. The final 
guidelines and regulations will probably enter 
into force in 2010. The Directorate of Health gave 
the following reasons for the professional guide-
lines: 
5.1 Strategy/policy 
The four regional health authorities are responsi-
ble for ensuring that specialist health services also 
include the treatment of drug and alcohol prob-
lems. In the Act relating to specialist health ser-
vices, the services are referred to as ’interdisciplin-
ary specialist treatment for problem drug and 
alcohol use’. This means that the services have 
both a social and health-related component.
The Norwegian Action Plan on Alcohol and 
Drugs (2008-2010) focuses on strengthening 
both the quality and the quantity of the treat-
ment services. Pursuant to the Action Plan, the 
quality and capacity of the services for patients 
with drug and alcohol problems must be impro-
ved. The national budget for 2009 specifies that 
there is still a need for greater growth in interdis-
ciplinary specialist treatment than in somatic 
services. To increase capacity, the following se-
ven measures will be implemented:
•	 Increase	efforts	and	treatment	capacity	in	
interdisciplinary specialist treatment, 
including medication assisted treatment
•	 Ensure	better	procedures	for	holistic	
treatment to avoid interruptions to treatment
•	 Increase	efforts	and	treatment	capacity	in	
mental health care services and ambulant 
services for people with both drug/alcohol 
problems and mental health problems
•	 Improve	the	service	for	patients	with	drug	
and/or alcohol dependency and mental 
health problems
•	 Amend	the	Patients’	Rights	Act	to	bring	it	
into line with the Administrative Alcohol 
and Drugs Treatment Reform
•	 Complete	professional	guidelines	for	
medication assisted treatment
•	 Consider	issuing	more	detailed	regulation	
for medication assisted treatment.
5.  Drug-related treatment: treatment  
demand and treatment availability 
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The guidelines must be viewed in conjunction 
with the regulations that regulate aspects of the 
treatment that are not regulated in other health 
legislation. 
5.2  Trends of clients in treatment 
and characteristics of treated 
clients
5.2.1 Data from the national client survey
Treatment demand data from treatment services 
are still only available at aggregate level. The in-
clusion of all admissions in the interdisciplinary 
specialist health service in the Norwegian Patient 
Register started from January 2009. It is possible 
that individual-based data can be reported from 
2010, but a further delay may occur. Overviews 
from the current national client mapping system 
do not tell us how many individuals are included 
in the number of queries and admissions, which 
means that it is impossible to control for double 
registration. Moreover, the data basis does not 
distinguish between problem users of alcohol 
and drugs. 
With these reservations, some preliminary data 
from the nationwide client mapping survey for 
2008 are included below (Erik Iversen, the Ber-
gen Clinics Foundation, personal communicati-
on). Comparisons are made with the correspon-
ding survey from 2006, data from which were 
presented in NR 2007, Chapter 4.2.1. 
In 2008, 34,952 requests for treatment were re-
ceived from a total of 106 reporting services. The 
figures include outpatient services, in-patient 
treatment and care-based services. In 2006: 
31,495 queries from 98 facilities. The number of 
admissions in 2008 was 24,422. In 2006: 21,987, 
while the number of concluded treatments was 
15,889. In 2006: 13,250. 
Most used intoxicant
Figure 8 shows that, except for alcohol, which 
still accounts for nearly half of the registrations 
on admission to treatment facilities and care ser-
“The evaluation of MAT in 2004 showed that un-
fortunate regional differences have developed in 
the country as regards waiting times, rehabilita-
tion efforts, the use of medication, organisation 
and the practising of the applicable guidelines. 
The criteria for receiving treatment and for being 
discharged from treatment differed. In addition, 
there were major differences with respect to mu-
nicipal follow-up services such as housing, em-
ployment and financial support. The overriding 
objective for the work was to incorporate MAT 
as an integral part of interdisciplinary specialist 
treatment for drug addicts”. (www.helsedir.no).
The proposed professional guidelines are largely 
a continuation of current practice, but some ad-
justments have been made as regards treatment 
indication and the basis for discharges. One par-
ticularly important change is that the minimum 
age for participating in the programme will be 
removed. It is currently 25 years. The main featu-
res of the proposal are: 
•	 The	treatment	indication	is	opioid	
dependency, in accordance with the 
currently applicable diagnostic criteria. 
However, substitution treatment should not 
be the first choice of treatment unless it is the 
most appropriate and adequate treatment 
option based on an overall assessment.
•	 No	minimum	age	is	set,	but	the	younger	the	
patient, the greater the emphasis on drug-
free treatment options.
•	 MAT	must	be	viewed	in	conjunction	with	
other available interdisciplinary specialist 
treatment options and the need for other 
specialist treatment for physical complaints 
and mental health problems.
•	 Treatment	will	start	in	the	specialist	health	
service. Tasks relating to the treatment, such 
as the ordering of medicinal drugs, may be 
delegated to the municipal health services, 
including GPs.
•	 The	use	of	other	substances	will	not	result	in	
patients being discharged, unless it entails an 
increased risk for the patient. Patients must 
only be discharged from treatment if the 
treatment is deemed to be unjustifiable or if 
the patient wishes to be discharged.
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Amphetamine and methamphetamine clearly 
predominate among the central stimulants. 
5.2.2  Profiles of clients in opioids  
substitution treatment 
Clients in opioids substitution treatment are in-
cluded in the nationwide client survey, but the 
probability of double registration is very small 
here since most of them stay in the same treat-
ment system all year. 
The Norwegian programme for medication assi-
sted treatment (MAT) has been discussed in pre-
vious reports to the EMCDDA. See NR 2004 
Chapter 5.3 in particular. Data are reported an-
nually in the form of status surveys from the 14 
regional centres that make up the MAT pro-
gramme (SERAF, 2009). For 2008, a total of 4,172 
forms were completed, while 4,913 persons were 
in treatment as of 31 December 2008. The avera-
ge age of clients (for whom a form has been com-
pleted) was around 40, and the proportion of 
women was approximately 30 per cent, both fi-
gures more or less unchanged since 2005. Four-
hundred and seventy-three patients concluded 
treatment during 2008, 39 of whom died. 
The number of patients has increased rapidly 
and steadily by approximately 500 per year. In 
2008, the total number of admissions was 831 
vices, heroin is most often reported as the most 
used intoxicant (18%). The percentage reporting 
heroin is in strong decline, however. In 2006, it 
was 24 per cent, while in the early 2000s it was 
around 35 per cent. The gender differences have 
evened out; the proportion of women reporting 
heroin was much higher a few years ago. 
The percentage reporting addictive medicinal 
drugs, including methadone and Subutex6, has 
increased somewhat, from 11 per cent in 2006 to 
approximately 14 per cent in 2008. The cor-
responding figure in the early 2000s was only se-
ven to eight per cent. The increase is probably 
largely due to substitution drugs, which acco-
unted for about eight per cent in 2008. The signi-
ficant differences between women and men, both 
in 2008 (19% and 12%) and in 2006 (16% and 
9%), are probably due to the use of lawfully pres-
cribed benzodiazepines. For substitution drugs, 
there is little or no difference between men and 
women. 
There was no change for cannabis and central 
stimulants as the most used intoxicants from 
2006 to 2008. The gender differences are also sta-
ble for both substance groups. In 2008, cocaine 
was registered separately, but only one per cent 
report it as being their most used intoxicant. 
6 Total of both lawfully prescribed and illegally used Subutex and 
methadone
Figure: 8. Most used intoxicant 2008. Percentage. 
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Psychosocial treatment 
The survey does not specify in detail the type of 
treatment measures the individual centres use 
beyond listing the services that the patient has 
been in contact with during the last 30 days. Ac-
tive rehabilitation usually requires regular inter-
disciplinary contact. The survey shows that just 
over six in ten have been in contact with the so-
cial centre at least once, nearly six in ten with 
their GP and almost five in ten with an MAT 
consultant. Nearly five in ten have attended a 
meeting of the team responsible for them. This 
indicates fairly frequent interdisciplinary contact 
but says little about the quality. The system de-
pends on competence in the first line and/or ac-
tive follow-up by MAT. Contact with other spe-
cialist health services is infrequent. Less than one 
in ten has had contact with psychiatric health 
services, despite considerable comorbidity. 
Drug use 
The reporting was carried out by combining in-
formation about drug use and results from urine 
sample controls. The measure used is any use of 
other substances than those prescribed by the 
programme during the last 30 days, confirmed 
by at least one positive urine sample and/or in-
formation about use of the drug. The same per-
son may test positive for more than one sub-
stance. The percentages are calculated separately 
for each substance. 
About 13 per cent have used opioids and approxi-
mately 15 per cent have used other central stimu-
lants in 2008. The use of cannabis is higher (32%), 
but the biggest problem is the use of benzodia-
zepines. More than 42 per cent have used such 
substances. Just under half of them (19%) had 
been legally prescribed the substance, while more 
than half obtained all such substances from illegal 
sources. The variation in this area is particularly 
great. One centre detected the use of benzodia-
zepines in 16 per cent of their patients, while the 
highest proportion at another centre was 53 per 
cent. A high proportion of legal prescriptions does 
not seen to prevent the use of medicinal drugs 
from illegal sources (SERAF, 2009). 
nationwide, 59.5 per cent of which were first-ti-
me admissions. The percentage of first-time ad-
missions has declined steadily in recent years, 
while the number of re-admissions is increasing. 
Social condition 
The status surveys have shown that a high pro-
portion live in independent living arrangements, 
while a low proportion have been rehabilitated 
in relation to the employment market, and a sig-
nificant percentage have disability benefit as their 
primary source of income. The percentage of 
people who are dependent on social security has 
varied considerably, also in 2008. Eight out of ten 
have their own house or apartment, two to three 
are in full or part-time employment and/or are 
in education/training, four in ten receive disabil-
ity benefit and one to two in ten rely on social 
security as their main source of income. In other 
words, rehabilitation does not usually lead to 
paid work and financial independence, but to 
disability benefit and social security benefits. In 
addition, many have been without work for years 
and have no qualifications. It is natural, there-
fore, that many are entitled to disability benefit. 
State of health 
The survey describes patients’ status regarding 
infections and mental and physical health using 
rough and fairly uncertain measures. Just over 
two per cent are HIV positive. Those who are 
HIV positive mainly live in Oslo and Akershus, 
and partly in surrounding counties. More than a 
quarter, 27 per cent, suffer from illnesses or inju-
ries that are sufficiently serious to affect their 
quality of life. Seventeen per cent show signs of 
serious depression and 21 per cent of serious 
anxiety. These findings are more or less un-
changed from previous years and confirm that, 
as a group, patients in MAT are characterised by 
considerable morbidity, both mental and somat-
ic. This largely involves enduring and, in part, 
chronic conditions. 
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riving in Norway for the first time. Four of them 
lived in Oslo. The number of HIV cases remains 
relatively low, and little new infection is detected 
in this group.
As of 31 December 2008, a total of 553 persons 
had been diagnosed as HIV positive with injec-
ting use as a risk factor. This amounts to 14 per 
cent of all reported cases of HIV since 1984. De-
velopment into AIDS has been reported in 149 
of the cases (Table 7). No information is available 
regarding how many of the HIV positive injec-
ting drug users are still alive. 
6.1  Drug-related infectious  
diseases 
See data in Standard table 09.
6.1.1 HIV and AIDS
In 2008, 299 cases of HIV infection were report-
ed to the Norwegian Notification System for In-
fectious Diseases (MSIS). Twelve of the cases 
were among injecting drug users: seven men and 
five women. The median age was 33 years (25 to 
53 years). Five of the twelve who were diagnosed 
as HIV positive in 2008 were persons of foreign 
origin. They had been infected abroad before ar-
6. Health correlates and consequences 
Table 7: Percentage of injecting drug users of persons infected by HIV and AIDS, with injecting risk behaviour, 
by year of diagnosis.
HIV total
HIV injecting 
drug use
Percentage HIV 
injecting drug 
use
AIDS total
AIDS injecting 
drug use
Percentage 
AIDS injecting 
drug use
1984-89 894 315 35% 142 8 6%
1990 90 22 24% 60 13 22%
1991 142 16 11% 57 14 25%
1992 105 12 11% 52 8 15%
1993 113 13 12% 63 13 21%
1994 94 13 13% 74 19 26%
1995 105 11 10% 67 7 10%
1996 116 9 8% 56 11 20%
1997 114 11 10% 35 8 23%
1998 98 8 8% 36 4 11%
1999 147 12 7% 31 7 23%
2000 175 7 4% 35 5 14%
2001 157 8 5% 33 8 24%
2002 205 16 8% 34 4 12 %
2003 238 13 5% 53 6 11%
2004 251 15 6% 36 4 11%
2005 219 20 9% 32 4 13% 
2006 276 7 3% 32 4 13%
2007 248 13 5% 11 0 0%
2008 299 12 4% 18 2 11%
Total 4,086 553 14% 957 149 16%
Source: Norwegian Institute of Public Health 
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ving new infection with hepatitis C and cases 
where the infection occurred many years ago. It 
is therefore not known whether new infection of 
hepatitis C among drug users has declined or in-
creased in recent years. 
In recent years, small-scale prevalence surveys 
have been carried out in connection with needle 
distribution in Oslo in order to register the inci-
dence of, for example, hepatitis among injecting 
drug users. These surveys are the only prevalence 
surveys that are carried out regularly among a re-
presentative sample of drug users in Norway. The 
2008 survey showed that 70 per cent of the 170 
persons included in the survey had experienced a 
hepatitis A infection or been vaccinated against 
the disease, 41 per cent of the 172 persons inclu-
ded in the survey had had a hepatitis B infection 
and 68 per cent of the 171 persons included in the 
survey had experienced a hepatitis C infection. 
Forty-three percent had tags indicating that they 
had been vaccinated against hepatitis B. 
6.2  Drug-related deaths and 
mortality of drug users 
See data in Standard tables 05 and 06.
Methodological considerations
In Norway, there are two bodies that register drug 
deaths, Statistics Norway (SSB) and Kripos. Kri-
pos bases its figures on reports from the police 
districts, while Statistics Norway prepares figures 
on the basis of medical examiners’ post-mortem 
examination reports and death certificates in ac-
cordance with the WHO’s ICD 10 codes. 
With effect from 1996, Statistics Norway’s figures 
have been based on EMCDDA’s definition of 
drug deaths. This broadened the inclusion crite-
rion that had been used until then. In the period 
since 1996, Statistics Norway’s figures have been 
consistently higher than the figures from Kripos. 
However, if suicide (by using drugs) and drug 
deaths among elderly people above the age of 65 
are eliminated from Statistics Norway’s statistics, 
the difference is smaller, although still conside-
The incidence of HIV among injecting drug 
users in the group has remained at a stable, low 
level, with about 10 to 15 cases reported per year. 
The reason for this is not entirely clear, but a high 
level of testing, great openness regarding HIV 
status within the user milieus, combined with a 
strong fear of being infected and strong internal 
justice in the milieu, are assumed to be impor-
tant factors. In addition, many of the sources of 
infection in the milieu have disappeared due to 
overdose deaths or have been rehabilitated 
through substitution therapy or other forms of 
rehabilitation. However, the extensive outbreaks 
of hepatitis A and B during the last ten years, and 
the high incidence of hepatitis C, show that there 
is still extensive needle sharing among this 
group. 
6.1.2 Hepatitis
During the nationwide outbreak of hepatitis A 
from 1996 to 2000, 1,360 drug users were identi-
fied as having acute hepatitis A. Since then, only 
sporadic, individual cases of hepatitis A have 
been reported among injecting drug users. 
Since 1996, there has been a considerable increa-
se in hepatitis B among drug users. In 2008, 54 of 
a total of 103 reported cases of acute hepatitis B 
were among injecting drug users. During the pe-
riod 1995 to 2008, the total number of reported 
cases of acute hepatitis B among injecting drug 
users was 1,924. 
The monitoring of hepatitis C in Norway was in-
tensified from 1 January 2008. The notification 
criteria were changed so that all laboratory-con-
firmed cases of hepatitis C must now be reported 
to MSIS. Previously, only acute illness had to be 
reported, and this provided a very inadequate 
overview of the real incidence of the disease in 
the country. In 2008, 3,411 cases of hepatitis C 
were reported. In about half of the reported ca-
ses, no information was provided about the pre-
sumed mode of transmission, but in the cases 
where the mode of transmission is known, 89 
per cent (1,680/1,890) were infected through the 
use of needles. For the time being, data from 
MSIS cannot distinguish between cases invol-
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In the early 1980s, the proportion of drug-related 
deaths among those over the age of 30 was less 
than 20 per cent. The proportion has increased 
steadily, and in the 1990s it had reached 60 per 
cent according to SSB’s statistics. The SSB statis-
tics show that, for the years 1996 to 2007, the 
proportion of drug deaths in the 30 plus age 
group was approximately 70 per cent on average. 
During the same period, the proportion over the 
age of 50 appears to have increased. The youn-
gest age groups’ proportion of deaths remained 
stable during the period 1996 to 2007 (Figure 9). 
During the period 1996 to 2007, the proportion of 
women varied between 15 and 27 per cent, and 
was close to 22 per cent on average (Figure 10). 
During the period 1980 to 1990, the average pro-
portion of women was also close to 22 per cent. 
Seen in a longer-term perspective, therefore, both 
the level and the variation seem to be within the 
‘normal range’ for the proportion of women. 
rable in some years. The trends are largely identi-
cal in both series of figures, however.
WHO revised its coding of causes of deaths rela-
ting to drugs and alcohol in 2002. The revisions 
were implemented in the Norwegian Causes of 
Death Register as early as 2003, but they were 
not included in the Standard Tables until last 
year. The corrected figures show a higher esti-
mate than previously reported by SSB. 
Situation and development 
The figures from both SSB and Kripos peak in 
2000/2001. In the ensuing years, there has been a 
considerable reduction in the number of regis-
tered drug deaths. The reduction since the turn 
of the millennium is most probably due to the 
strong increase in the number of clients on med-
ication assisted treatment. Both the SSB figures 
and the Kripos figures appear to indicate that, af-
ter the reduction following the peak years of 
2000 and 2001, a certain stabilisation of the num-
ber of drug-related deaths has occurred. 
According to the statistics from Kripos for 2008, 
24 of 27 police districts had registered drug-rela-
ted deaths. Oslo had most deaths (60), 34 per 
cent of the total. Very many of the deaths are be-
lieved to be due to extensive multiple use. 
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Figure 10: Drug-related deaths broken down by 
gender, 1996-2007. Percentage
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Figure 9: Drug-related deaths broken down by age 
group, 1996-2007. Percentage
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Table 8: Drug-related deaths 1991-2008. Total number of deaths and broken down by gender. Figures from 
Kripos and Statistics Norway (underlying cause of death).
1991-2008 Number of deaths according to Kripos Number of deaths according to Statistics Norway *
Men Women Total Men Women Total
1991 74 22 96 66 22 88
1992 78 19 97 81 23 104
1993 77 18 95 76 17 93
1994 102 22 124 105 19 124
1995 108 24 132 114 29 143
1996 159 26 185 173 31 204
1997 149 28 177 160 34 194
1998 226 44 270 228 54 282
1999 181 39 220 191 65 256
2000 264 63 327 302 72 374
2001 286 52 338 327 78 405
2002 166 44 210 240 67 307
2003 134 38 172 193 62 255
2004 168 55 223 220 83 303
2005 146 38 184 176 58 234
2006 152 43 195 187 64 251
2007 162 38 200 217 58 275
2008 148 31 179 ** ** **
Source: Kripos and Statistics Norway 
*The Statistics Norway’s figures from 1996 and subsequent years are based on a revised inclusion criteria including a higher number 
of ICD-codes. Suicides in which narcotic substances were used are included from 1996.This results in higher estimated drug-related 
deaths. Hence the figures before and after 1996 are not directly comparable. Following WHO’s classification instructions for certain 
drug-related deaths, Statistics Norway introduced a revised coding of causes in 2003. This also creates a higher rate of estimated 
drug- related from 2003 and subsequent years. 
** Figures from Statistics Norway for 2008 are not yet available.
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alcohol problems and mental health problems 
(see Chapter 5.1). Those who are referred to in-
terdisciplinary specialist treatment for drug and/
or alcohol dependency will also be evaluated 
with respect to whether they need other services 
in the specialist health service. It is also a goal 
that users should become more involved in the 
work in this field. Psychiatric District Centres 
must have the competence and staff required to 
attend to individual and multiple treatment 
needs in all patients who are referred to mental 
health care services. The hospitals will be respon-
sible for expert functions. 
The Directorate of Health’s reporting as of 31 
December 2008 shows that all the health regions 
are working to improve services for patients with 
concurrent problems. For example, the South-
Eastern Norway Regional Health Authority has 
placed great emphasis on strengthening its capa-
city in relation to acute measures and examinati-
ons in order to ensure that the needs of people 
with drug/alcohol dependency are assessed in 
relation to other specialist health services. Medi-
cal competence in the public sector part of inter-
disciplinary specialist treatment in Oslo has been 
considerably strengthened (the Directorate of 
Health, 2009). 
7.1  Psychiatric and somatic  
comorbidity 
Guidelines for serious mental health problems 
and drug and alcohol-related problems
The Directorate of Health has started work on 
drawing up national professional guidelines for 
diagnosing, treating and following up patients 
with serious mental health problems and con-
current drug and/or alcohol problems. The 
guidelines will deal with three main areas: 
Knowledge about concurrent serious mental •	
health problems and drug or alcohol 
dependency/problem use 
Recommended methods for examination •	
and diagnosis 
Recommended treatment and other follow-up.•	
The key elements in the proposed guidelines 
were discussed in NR 2008, Chapter 7.3.1. The 
guidelines were distributed for consultation early 
in 2009 and are expected to be completed by au-
tumn 2009. 
As part of the Action Plan (2008-2010), the ef-
forts and treatment capacity of the mental health 
care services and ambulant services will also be 
increased for those with concurrent drug and/or 
7.  Responses to health correlates  
and consequences
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grant scheme for municipal efforts in the drug 
and alcohol field has been substantially strengt-
hened in 2009. The aim is to encourage greater 
use of individual plans, including comprehensive 
follow-up before, during and after stays in insti-
tutions or in prison. Social inclusion and fewer 
relapses are other important goals. Increased use 
of individual plans is one of the main target areas 
of the grant scheme ‘Municipalities’ follow-up of 
problem drug and alcohol users’ and in the trial 
scheme involving coordinating representatives.
8.1.2  Trial scheme involving coordinating 
‘representatives’ for people with 
drug or alcohol dependency in the 
municipalities
A three-year trial has started involving coordi-
nating representatives in 30 selected municipali-
ties. The aim of having such representatives is to 
help to ensure more coherent and individually-
adapted services for people with drug or alcohol 
dependency, thus resulting in greater social in-
clusion and better life coping. The representa-
tives will follow users through the help services 
and ensure that they get the services they need, 
such as work/activity, medical help, housing, fi-
nancial guidance, network-building, help in con-
nection with crises etc. The municipalities can 
cooperate with voluntary organisations, but the 
offer must be based on the Social Services Act in 
order to comply with case processing require-
ments and ensure that users enjoy due process 
protection.
8.1.3 Qualification programme 
The goal of the qualification programme is to 
strengthen efforts targeting persons with signifi-
cantly impaired work capacity and earning abili-
ty who have limited or no National Insurance 
rights. The qualification programme will give 
people with drug or alcohol dependency a better 
8.1 Social reintegration 
New measures in the Action Plan (2008-2010) 
are discussed in Chapters 8.1.1 – 8.1.4. 
8.1.1 Increased use of individual plans
As of 1 January 2004, the right to an individual 
plan for drug and alcohol users in need of long-
term, coordinated services was laid down in the 
Act relating to social services (section 4-3a). The 
right to a plan based on individual treatment ad-
aptation and further follow-up was already en-
shrined in the Patient’s Rights Act in 2001. How-
ever, several reports show that few people with 
drug or alcohol dependency actually have an in-
dividual plan. The Action Plan therefore aims to 
ensure that more drug and alcohol users get their 
own plan.
Everyone who is in need of long-term, coordina-
ted health and social services is entitled to an in-
dividual plan. The plan should include the ap-
pointment of a coordinator who is responsible 
for follow-up of the user and for the progress of 
the plan. There should also be a responsible team 
consisting of the user, the coordinator and other 
natural partners, such as the GP, family members 
or others. By having an individual plan, the user 
will have the benefit of a better overview of the 
services, more active participation and targeted 
cooperation. The support services will benefit in 
the form of better coordination of their services, 
a clearer user focus and more binding relations 
with the users. 
The Directorate of Health is working to increase 
the use of individual plans for all groups who 
need or are entitled to such plans. Several mea-
sures have been initiated to ensure that more 
such plans are drawn up for problem drug and 
alcohol users. As mentioned in Chapter 1.3, the 
8. Social correlates and social reintegration 
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ing services for people with drug or alcohol 
problems:
Increase efforts to eradicate homelessness – •	
with particular focus on homelessness in 
small municipalities
Increase efforts to prevent homelessness, •	
including reducing the number of evictions 
and temporary housing arrangements
Develop methods and procedures for •	
following up people in temporary housing 
arrangements so that they can be offered a 
permanent solution
Introduce a new investment grant for •	
nursing homes and sheltered housing.
All four measures were initiated in 2008. In addi-
tion, a trial project has been initiated to reduce 
the number of evictions and temporary housing 
arrangements. The Obtaining housing for one-
self strategy will be evaluated, and a new survey 
was carried out in November 2008. These two re-
ports will tell us whether smaller municipalities 
have also succeeded in putting homelessness on 
the agenda, without efforts decreasing elsewhere. 
They will also tell us something about the mea-
sures that did not work.
The Correctional Services have received funding 
from the Ministry of Local Government and Re-
gional Development via the State Housing Bank 
to provide housing for inmates on their release 
from prison. Efforts are being made to draw up 
agreements with the individual municipalities. 
The correctional services have received grants to 
fund the appointment of seven housing advisers. 
At the end of 2007, a total of 44 cooperation 
agreements had been entered into between regi-
ons/prisons and the individual municipalities 
(the Directorate of Health, 2009).
opportunity to take part in the employment mar-
ket and in other activities. The programme must 
be individually-adapted and work-related, so 
that it supports and paves the way for the transi-
tion to employment. The programme has been 
implemented in all municipalities with NAV7 of-
fices. The scheme will be nationwide from 1 Jan-
uary 2010. 
The most recent reporting shows that, during the 
second half of 2008, far more applications for 
programmes were registered than in the first 
half-year, and the number of participants has in-
creased significantly. At the end of 2008, the sc-
heme was available in 276 municipalities. During 
2008, a total of 5,279 applications were received. 
Of the applications that had been processed by 
the end of the year, 4,411 were granted and 160 
were rejected. The number of participants at the 
end of the year was 4,133. 
Work is being done to strengthen cooperation 
with NAV in order to ensure that more convicted 
persons who are serving prison sentences can find 
employment or join a qualification programme 
on their release. There are eight NAV advisers in 
prisons. They cooperate with the other NAV offi-
ces on prisoner releases. The goal is to increase the 
number of regional and local agreements between 
the correctional services and NAV.
8.1.4  Strengthen housing services  
for people with drug or alcohol 
problems 
The proportion of homeless people with a drug 
or alcohol problem was 59 per cent in 2008. In 
recent years, several housing and service models 
have been developed, such as the Homeless peo-
ple project and Obtaining housing for oneself. 
The Action Plan specifies that these initiatives 
will be continued and that the experiences from 
them will be spread to more municipalities. The 
following four measures aim to strengthen hous-
7 Norwegian Labour and Welfare Service-NAV
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cent in 1998, drug crime was the primary offence 
in 41 per cent of all criminal cases in 2007. 
In 2007, the total number of convictions for drug 
offences was 14,430 (number of cases). Only 1,220 
convictions resulted in unconditional prison sen-
tences. Of these, 663 were sentenced to a combi-
nation of an unconditional prison sentence and a 
fine, while 358 cases resulted in both unconditio-
nal and suspended prison sentences. The number 
of fines was as high as 10,646, while community 
sentences were imposed in 446 cases. 
9.1.2 Organised crime in Norway
A report published by the National Police Direc-
torate in 2009 contains a strategic analysis of or-
ganised crime in Norway. See also Chapter 
10.2.2. The purpose of the report is to shed light 
on the complexity of organised crime and the 
challenges it poses for the police in relation to 
preventing and combating crime. The report is 
also intended to make it easier for the police to 
agree on a national strategy based on analyses 
and intelligence. 
9.1 Drug-related crime 
9.1.1 Drug law offences
Reported drug crimes
In 2008, the police registered 37,531 drug offences. 
That is almost 3,300 fewer than in 2007 and one of 
the lowest figures in the last ten years, equivalent to 
the level during the period 2003 to 2005. 
The decline from 2007 was somewhat greater for 
drug offences that are regulated by the Act rela-
ting to medicines (9%) than for more serious 
drug offences regulated by the General Civil Pe-
nal Code (7%). The number of reported viola-
tions of the two acts was almost equal, 19,191 
and 18,340, respectively (Table 9). Figures for the 
number of investigated offences are not available 
from Statistics Norway after 2005.
Penal sanctions 
The most recent data from Statistics Norway, 
from 2007, are described in NR 2008, Chapter 
8.2.1. Penal sanctions for drug crimes have in-
creased most during the last decade and have 
contributed to a change in which groups of 
crimes result in penal sanctions. From 33 per 
9.  Drug-related crime, prevention  
of drug-related crime and prison
Table 9: Number of reported drug crimes 2003-2008.* 
2003 2004 2005 2006 2007 2008
Drug crimes 15,009 15,671 16,163 17,966 17,779 16,475
Aggravated drug crimes 1,143 1,143 955 1,190 1,307 1,072
Other drug crimes 578 501 485 568 658 793
Total pursuant to General Civil Penal Code, year 2008 18,340
Drugs, use 10, 547 10,925 11,259 12,635 12,806 11,585
Drugs, possession 8,533 8,364 8,070 8,627 7,562 7,005
Drugs, miscellaneous 901 715 731 747 659 601
Total pursuant to Act related to medicines, year 2008 19,191
Total number reported 36,711 37,319 37,663 41,733 40,771 37,531
* Number of cases
Source: Statistics Norway
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Operation ’Green Lamp’, targeting the Vietnamese 
cannabis plantations, highlighted some of the chal-
lenges described above. It was already known that 
such plantations constituted a big problem for the 
police in other European countries, but there was 
no intelligence information indicating a large num-
ber of plantations in Norway. The reason that the 
first plantation was uncovered was that someone 
had done a poor job when connecting the electri-
cal system, which caught fire. Afterwards, it was 
revealed that the Norwegian police were aware of 
a radical increase in the number of marijuana sei-
zures, but that the information had not been linked 
to the possible presence of illegal plantations” (the 
National Police Directorate, 2009).
9.2 Other drug-related crime
9.2.1 Driving offences
In 2008, the Division of Forensic Toxicology and 
Drug Abuse at the Norwegian Institute of Public 
Health performed around 10,000 analyses of driv-
ers suspected of driving under the influence. Of 
these, 4,500 were blood samples on which a broad 
analysis was carried out, i.e. analyses of alcohol 
and the most frequently found intoxicants (Figure 
11). As a rule, several substances were found in 
the same blood sample. In the blood samples 
where a broad analysis was carried out, an average 
of three intoxicants were found. In addition to al-
cohol, there is a high incidence of THC, diazepam, 
amphetamine and methamphetamine in the sam-
ples (Table 10 and Figure 12). 
Figure 11: The number of road traffic cases re-
ceived involving suspicion of being under the influ-
ence of either alcohol or other substances. 
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The main part of the report consists of an analy-
sis of the five areas of organised crime that are 
seen as particularly challenging:
•	 A	comprehensive	effort	in	relation	to	cocaine
•	 Preventing	and	combating	criminal	gangs
•	 Efforts	targeting	crimes	against	property,	with	
particular focus on receivers of stolen goods
•	 Uncovering	the	ringleaders	behind	human	
trafficking and smuggling
•	 Uncovering	money	laundering	and	
confiscating the proceeds of criminal offences.
According to the report, “Very few police dis-
tricts mention organised crime as a threat in 
trend reports and analyses of the crime situa-
tion. One explanation may be that smaller oper-
ational units lack the knowledge, resources and 
expertise required to uncover and investigate or-
ganised crime. A number of police districts do 
not have analysis units with their own analysts. 
The strategic reports prepared by the police dis-
tricts therefore vary greatly in terms of scope 
and quality. A lack of internal communication, 
experience and expertise in this type of report-
ing may be the reason for this. Previously, most 
of the cases that involved seizures of large quan-
tities of drugs were followed up in order to un-
cover the rest of the drug network. Today, there 
is limited capacity for this”. 
The report also provides an illustration of the 
current situation as regards seizures made along 
Norway’s borders: 
“In a selected period of eight weeks from 1 Septem-
ber to 31 October 2008, 14 seizures were made on 
the Swedish border (Østfold police district). In 
terms of quantities, these seizures amounted to a 
total of 60 kg of drugs. Nine of the cases were big 
enough to be regarded as very serious drug offen-
ces pursuant to the General Civil Penal Code sec-
tion 162 third paragraph. Of the 14 cases, the po-
lice only made efforts to uncover the receivers and 
ringleaders in three of the cases.
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also contain amphetamine even if the person in 
question has not necessarily used both drugs. It 
is therefore misleading to simply add up the figu-
res for methamphetamine and amphetamine. 
The relationship between amphetamine and 
methamphetamine in road traffic cases is inves-
tigated in more detail in Chapter 12. 
In recent years, methamphetamine has been in-
creasingly present in blood samples from drivers 
in Norway, while the trend for amphetamine ap-
pears to be slightly declining. This may indicate 
that amphetamine is increasingly being replaced 
by methamphetamine. However, some of the 
methamphetamine used metabolises into amp-
hetamine in the body. Many of the blood samples 
that contain methamphetamine will therefore 
Figure 12: Finds of illegal drugs in road traffic cases received 2000-2008. In numbers. 
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Table 10: The most common finds of substances other than alcohol in blood samples from drivers suspected 
of driving under the influence in 2008. The number and percentage of blood samples on which a broad 
analysis was carried out.
 Name of substance
Example of name of medicine  
Explanation
Total number 
4,525
Percentage
1 THC Active agent in cannabis 1,305 29%
2 Diazepam Valium ® Vival ® Stesolid ® 1,203 27% 
3 Amphetamine  1,191 26%
4 Methamphetamine  1,098 24%
5 Clonazepam Rivotril ® 715 16% 
6 Nitrazepam Apodorm® Mogadon® 319 7% 
7 Alprazolam Xanor® 306 7%
8 Oxazepam Sobril® Alopam® 251 6% 
8 Morphine Heroin Dolcontin® Paralgin forte® 251 6% 
10 Benzoylecgonine Cocaine metabolite 201 4% 
11 Flunitrazepam Flunipam® Rohypnol® 188 4% 
12 Codeine Paralgin forte® 174 4% 
13 Methadone  132 3%
14 Zopiclone Imovane® Zopiclone® 102 2% 
15 Zolpidem Stilnoct® 69 1.5%
Source: Norwegian Institute of Public Health 
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9.3.2  Other interventions in the criminal 
justice system
Alcohol treatment programme
In 2008, 485 suspended sentences were imposed 
on condition of alcohol treatment programmes, 
compared with 467 in 2007. Eighty per cent were 
completed without the conditions being breached 
or new crimes being committed. 
Suspended sentence with Drug Courts 
Drug Courts are an alternative to prison for peo-
ple with drug and/or alcohol dependency who 
have been convicted of drug-related crimes. The 
participants regularly attend a day centre where 
rehabilitation is offered by an interdisciplinary 
service team. The programme was originally a 
three-year trial project in 2006 in Oslo and Ber-
gen. The project has been prolonged until 2011 
and is currently being evaluated by SIRUS. In 
2008, 29 new sentences were implemented; 13 in 
Oslo and 16 in Bergen. Twenty-four suspended 
sentences were completed in 2008. Four sentenc-
es were completed without the conditions being 
breached, while the rest were interrupted, mostly 
because of new crimes being committed.
9.4  Drug use and problem drug 
use in prisons 
See also Standard table 12.
The use of drugs and alcohol and illegal con-
sumption of medicinal drugs during the serving 
of sentences has been stable in recent years. Bas-
ed on reports received by the central administra-
tion for the correctional services for 2008, it is 
evident that the number of seizures of drugs, al-
cohol and medicinal drugs has not changed sig-
nificantly. The number of finds of user equip-
ment and manufacturing equipment is also 
relatively stable 
Urine samples to control drug use among inmates 
show that use is fairly stable compared with previ-
ous years. The National Institute of Public Health 
carried out analyses of almost 26,000 urine samples 
The number of drivers caught with cocaine (ben-
zoylecgonine) in the blood has increased during 
the last year. From slightly less than 150 drivers 
the year before, the number of drivers under the 
influence of cocaine registered last year was abo-
ut 200. This is the highest number in eight years. 
Men living in Oslo and central parts of Eastern 
Norway stand out with most positive samples 
(Norwegian Institute of Public Health, 2009). 
9.3  Interventions in the criminal 
justice system 
9.3.1 Alternatives to prison 
Serving of sentences outside institutions 
pursuant to the Execution of Sentences Act 
section 12
So-called section 12 sentences are the most com-
mon alternative for convicted felons with drug 
or alcohol problems. See NR 2007 and NR 2008, 
Chapter 9.2, for more information. In 2008, the 
number of sentences started pursuant to section 
12 of the Execution of Sentences Act was 505, 
which is a marked increase on previous years. Of 
these, 257 started alternative sentences immedi-
ately after conviction, while 248 felons were 
transferred after serving the first part of a sen-
tence in prison. The proportion of women was 
approximately 15 per cent. The number of days 
served pursuant to section 12 has also increased 
and amounted to almost 45,000 days in 2008 
(Table 11). 
Table 11: Number of days served pursuant to 
section 12, 2003-2008.
2003 2004 2005 2006 2007 2008
Men 31,673 26,302 34,474 37,137 37,835 40,150
Women 2, 729 2,235 3,786 4,347 4,224 4,841
Total 34,402 28,537 38,260 41,484 42,059 44,991
Source: The central administration of the correctional services 
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9.5  Responses to drug-related 
health issues in prisons
Units for mastering drug and alcohol problems
The Ministry of Health and Care Services and the 
Ministry of Justice and the Police are working to-
gether to establish units aimed at mastering drug 
and alcohol problems in prisons. Units aimed at 
mastering drug and alcohol problems are a new re-
habilitation service for inmates with drug and/or al-
cohol dependency who are entitled to interdisciplin-
ary specialist treatment. The treatment is provided 
by the specialist health service, and staffing of the 
correctional services has also been strengthened in 
this connection. The aim is that a stay in a unit for 
mastering drug and alcohol problems will be fol-
lowed up with outpatient treatment or treatment in 
an institution upon release. Three units opened in 
2008 and six more will open during 2009, bringing 
the total number of prison units to nine. In addition, 
a new Pathfinder unit for female inmates was opened 
in 2008 in Bredtveit prison in Oslo (The central ad-
ministration of the correctional service). 
from prisons in 2008, approximately 1,500 more 
than in 2007. Drugs and tranquilisers were found 
in more than 6,500 of the samples, which is the hig-
hest number ever. After the samples had been qua-
lity assured to check whether there had been any 
use of drugs or legal medication during the time 
the inmates served their sentences, just over ten per 
cent of all the samples were classified as illegal use. 
The other positive samples were due to the use of 
drugs before arrival in prison or following the use 
of legal medication. 
Figure 13 shows that cannabis, amphetamine, met-
hamphetamine8 and various tablets are the most 
frequently discovered drugs. As regards methado-
ne, it is not known to what extent it was used ille-
gally. The number of inmates receiving legal medi-
cation from health personnel has increased. The 
prisons are cooperating with the health enterprises 
in connection with medication assisted treatment 
of inmates who are heavy drug addicts.
8 The ratio between methamphetamine and amphetamine is 
studied in more detail in Chapter 12
Figure 13: Drug finds in correctional service cases 2000-2008. In numbers.
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The quantity of heroin used is mainly calculated 
on the basis of various special surveys among he-
roin users who provide information about their 
use and the quantity taken each time. There is 
great variation in the quantity of heroin used, 
both within the group of problem users and, not 
least, between the three user groups. Calcula-
tions indicate that problem users who inject the 
drug have an annual consumption of approx. 160 
grams, that those who smoke the drug use about 
118 grams, while those who both smoke and in-
ject the drug on average use about 140 grams a 
year. Sporadic heroin users are assumed to use 
heroin twice a month, which means an annual 
consumption of 6.6 grams. Naturally, experi-
mental users make the smallest contribution to 
total consumption. It is assumed that, on avera-
ge, those who experiment use heroin twice, so 
that each user takes 0.3 grams per year.
Unsurprisingly, problem users account for the 
majority of the heroin used in Norway. If, for 
example, the number of sporadic users changes, 
or the assumed quantity of heroin used changes, 
by 20 per cent, the total amount only changes by 
plus/minus five kilos (1,440-1,450 kg). If the num-
ber or quantity changes correspondingly for expe-
rimental users, the effect is minimal. A 20 per cent 
increase in the number of problem users, however, 
will change the estimated consumption figures by 
15 to 17 per cent (1,205-1,665 kg), and a cor-
responding change in consumption will change 
the estimated annual consumption by 16 to 20 per 
cent (1,160-1,730 kg). 
10.2 Supply 
10.2.1 Smuggling routes to Norway
According to the customs service, most of the 
amphetamine and methamphetamine on the 
Norwegian market comes from illegal laborato-
ries in the Netherlands, Poland and Lithuania. 
10.1 Availability 
10.1.1 Heroin use in Norway
In a new survey from SIRUS (Bretteville-Jensen 
and Amundsen, 2009), the estimated consump-
tion of heroin in Norway during the course of 
one year has been calculated for the first time. 
According to the survey, the quantity of heroin 
used in 2006 was estimated to be approximately 
1,445 kilos, while consumption in the period 
2000 to 2002 was estimated to be just over 2,000 
kilos. The decline is mainly due to a decline in 
the number of problem users. 2006 is the last 
year for which the data are good enough to stip-
ulate the number of problem users. However, the 
estimate for 2006 will probably also apply to 2007 
and 2008. 
A bottom-up method has been used to calculate 
heroin consumption, which estimates the num-
ber of persons who have used heroin in the co-
urse of a year and multiplies it by the estimated 
quantity used. The assumption is that heroin 
users can be divided into three groups; problem 
users, sporadic users and experimental users. 
Chapter 4.1.2 contains a more detailed account 
of the classification of different user groups and 
the methods used to calculate the number of 
users. 
For the problem user group, a distinction is also 
drawn between different methods of taking he-
roin, as this is thought to have a bearing on the 
quantity of heroin used. An estimated annual 
consumption has been calculated for problem 
users who only inject the drug, for those who 
only smoke it, and for those who both smoke 
and inject it. As regards sporadic and experimen-
tal users, the poor data basis means that a dis-
tinction cannot be drawn between the different 
methods of taking the drug.
10. Drug markets
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the UK. The largest quantities, however, are 
transported by road in cars from the Netherlands 
and Germany via Denmark and Sweden.
As before, cocaine comes from South America 
to Africa and Spain and from there to the Nether-
lands and Germany before continuing up 
through Denmark to Norway. Considerable 
quantities are also smuggled by airline passen-
gers who arrive at European airports directly 
from South America. The cocaine is smuggled 
on to Norway in various ways. The customs ser-
vice still uncovers many couriers smuggling the 
drug inside their bodies. 
LSD is smuggled in the post and in courier ship-
ments from Canada. The number of shipments is 
not high, but the trend is that the number is in-
creasing (the customs service, personal commu-
nication).
10.2.2  Geographical regions that affect the 
crime situation
The report from the National Police Directorate 
on organised crime in Norway (see Chapter 
9.1.2) claims that the Norwegian Police can ex-
pect an increased presence of international crim-
inal networks. This view is shared by cooperating 
European police authorities, and, on Norway’s 
part, this development is linked to three geo-
graphical regions: 
The report states the following about these regions: 
 South America and West Africa
“According to reports from Europol, West Afri-
can (Nigerian) criminal groups are increasingly 
involved in the smuggling of cocaine, organised 
prostitution and economic crime. The criminal 
networks are loosely organised and membership 
is based on religious, ethnic or geographical 
origin. It is thought that the groups are increas-
ing their activities relating to the smuggling of 
cocaine to Norway. The transport routes for co-
caine from Africa to Europe are often the same 
as for human trafficking and the smuggling of 
hash. Nigerian criminal groups are responsible 
for smuggling to Norway and they use the 
Lithuanian criminals have had a dominant role 
for several years as suppliers of synthetic drugs 
to Norway, and the proportion of amphetamine 
seized from Lithuania is increasing. However, 
the largest quantities of amphetamine seized now 
come from the Netherlands and Poland. The 
main routes go through Germany and Denmark 
via Sweden. Cars with concealed cavities still 
seem to be the most frequently used method. 
Cannabis seized in Norway mainly comes from 
Morocco via the Netherlands. From the Nether-
lands, hash is transported via Denmark and on 
to Norway by car, bus, train or plane. The cust-
oms service has uncovered large quantities of 
cannabis in passenger cars and heavy goods ve-
hicles. The proportion of smuggled marijuana is 
increasing. 
Ecstasy (MDMA) sold is largely produced in il-
legal laboratories in the Netherlands and Poland. 
The customs service makes most seizures in con-
nection with drugs sent in the post, while the 
biggest seizures are made in cars at Norway’s 
borders. 
GHB and GBL are smuggled in shipments from 
the Netherlands, Poland and the UK. Most of the 
seizures are sent in the post and as courier ship-
ments, while attempts are made to smuggle lar-
ger shipments by car. 
Heroin sold in Norway mainly comes from Afg-
hanistan through Turkey via two northerly ro-
utes through Bulgaria/Romania–Ukraine/Rus-
sia, and then on to Poland /Lithuania. Two 
southerly routes go through Greece/the Balkans 
to the Netherlands/Germany. From there, con-
signments destined for Norway are packed in 
hand luggage or passenger cars with concealed 
cavities. The number of couriers who smuggle 
heroin inside their bodies is increasing.
Khat is transported from production areas in 
Africa to Europe. It is smuggled on to Norway 
from the Netherlands and the UK by plane and 
car. Most of the seizures are made from airline 
passengers who arrive from the Netherlands and 
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ringleaders control activities relating to heroin 
smuggling and human trafficking from their 
home countries. The networks are increasingly 
distributing cocaine and amphetamine. In Swe-
den, organised criminals from the Balkans have 
dominated the heroin market and aggravated 
robberies. They have used extreme violence to 
achieve their goals. They have central roles in 
established gangs in Swedish cities.
Turkey is of central importance to the Balkan ro-
ute due to its position as the gateway to Europe.” 
The survey also mentions other geographical areas:
“Other players than before are getting involved, 
however, and this may affect the situation in 
Norway. OCTA 20089 refers to the fact that Ni-
gerian organisations buy large quantities of he-
roin from Turkish ringleaders and arrange for 
the heroin to be transported from Turkey to other 
European countries, including the Nordic coun-
tries. They use Nigerian networks that are estab-
lished in Europe/the Nordic countries, and the-
reby have a network that is highly suitable for 
the distribution of heroin. Transport is often car-
ried out using female couriers. Europol also 
points to increased activity among resourceful 
Pakistani criminal networks in Turkey.
There is reason to believe that an identified Kur-
dish group is involved in smuggling heroin from 
Turkey. The group is involved in the transporta-
tion of heroin to, for example, the Netherlands 
and Germany. The drug is transported on to 
drug dealers in the Nordic countries. Since the 
majority of Turks in Norway and the Nordic co-
untries are Kurds, there is reason to believe that 
the smuggling of heroin in this network will be a 
threat in the future. It is probable that the same 
network is involved in human smuggling, docu-
ment forgery and illegal currency exports”. (The 
National Police Directorate, 2009)
9 Europols Organised Crime Threat Assessment 2008 (OCTA)
Netherlands for intermediate storage. Here, co-
caine is divided, couriers are recruited and 
transport is organised. The smuggling takes pla-
ce by land, sea and air. The criminal groups are 
based in the Netherlands, Germany and Belgium 
and in the Nordic capitals. The Netherlands’ role 
as a contact/distribution point seems to be in-
creasing.
Lithuania and Poland
’Organised criminal groups from Lithuania and 
Poland dominate the smuggling of amphetamine 
and methamphetamine to Norway. Criminal 
groups handle the production, importation and 
distribution of amphetamine. Baltic groups, and 
Lithuanians in particular, travel between the 
Nordic countries committing aggravated crimes 
against property and smuggling drugs. Aggra-
vated violence is used both within the networks 
and against external victims. Organised crime 
from Lithuania has been highlighted as a threat 
by Europol and the Nordic countries. It is seen 
as likely that crime committed by Lithuanian and 
Polish criminals will increase in the time ahead. 
One example of what this threat may entail is an 
Estonian/Russian criminal group whose activi-
ties include armed robberies and the smuggling 
of drugs. The group committed murder and was 
involved in counterfeiting, kidnapping, car theft 
and human trafficking. The group’s main activi-
ties have ties to Norway, i.e. robberies and the 
smuggling of cocaine. One of the group’s (esti-
mated to about 30 members) Estonian cocaine 
couriers has been arrested in Norway.’
The Balkans and Turkey
’Organised criminals from the Balkan countries 
(from Albania and Macedonia in particular) 
have been one of the Norwegian police’s biggest 
challenges since the 1990s. The Balkan route is 
used for smuggling a number of goods. This af-
fects the situation in Norway as regards the 
smuggling of heroin, human smuggling, docu-
ment forgery, human trafficking and crimes 
against property. Organised criminals origina-
ting from the Balkans collaborate with a number 
of established criminal gangs in Norway. They 
are notorious for using extreme violence. The 
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the proportion seized is in any case low, especi-
ally in relation to the ‘ten-percent rule’ to which 
many people refer. 
10.3.2 Seizure statistics for 2008
See also the data in Standard table 13. 
Data basis and sources of error
The annual report from the National Criminal 
Investigation Service (Kripos) on the status of 
and developments in drug trafficking contains 
national data that include all seizures by the po-
lice, the customs service, the prisons and the 
Armed Forces. The data are based on verified 
analysis results for use in ordinary criminal cas-
es, as well as on information from the police dis-
tricts when drug offences are decided locally 
through fines or by summary trial based on a 
plea of guilty. The latter categories are decided 
without the seizures being tested at the Kripos 
laboratory. In these cases, relevant information is 
usually given about what the seizures probably 
contain. The sources of error are not deemed to 
have a significant bearing on the main trends, 
but experience indicates that some of the minor 
seizures may include other types of drugs than 
those stated in statements to the authorities.
Main features of the drug statistics for 2008
In 2008, 19,619 drug cases and 23,835 seizures 
were registered. Nationwide, this represents a 
decline from 2007 of four and three per cent, re-
spectively. However, there are big differences be-
tween the different types of drugs. It was also the 
case in 2008 that more drug cases were registered 
as having been decided by fines than ordinary 
criminal prosecutions. Of the total of 19,619 
drug cases, 8,406 were analysed, while 11,213 
were fixed-penalty cases. 
The quantities seized will naturally vary conside-
rably from one year to the next. As an indicator 
of the size of individual seizures, based on quan-
titative criteria for prosecution that meet the de-
finition of aggravated drug crime in the General 
Civil Penal Code section 162 third paragraph, 38 
such large drug seizures were made in both 2007 
and 2008 (Table 12). 
10.3 Seizures
10.3.1  Proportion of heroin seized in 
relation to estimated annual  
consumption
The survey of the consumption of heroin in Nor-
way (Chapter 10.1.1) also included calculations 
regarding the proportion of heroin seized in rela-
tion to estimated annual consumption. Apparent-
ly without a basis in the actual calculations, it has 
often been assumed that approximately ten per 
cent of the drugs that people try to import to the 
country are seized. The assumption has been 
widespread both in Norway and in other Western 
countries and has included seizures of heroin as 
well as other drugs. 
For the period 2000 to 2008, it is estimated that 
the total seizures by the police and the customs 
service amount to an average of only four per 
cent of the assumed total consumption of heroin 
in Norway per year. The highest proportion of 
seizures took place in 2004 (8% of annual con-
sumption), while the lowest proportion was sei-
zed in 2007 (less than 3%). Seizures made by the 
customs service for the period 2000 to 2008 
amount to about two per cent of the estimated 
annual consumption of heroin. As a proportion 
of consumption, their seizures were highest in 
2006 (6% of annual consumption) and lowest in 
2007 (less than 1%) (Bretteville-Jensen and 
Amundsen, 2009). 
Of course, there is uncertainty attached to these 
calculations, and the estimated proportion that 
is seized could change if it were to emerge that 
the actual number of problem users or the av-
erage quantity of heroin used is more or less than 
assumed. In that case, the total consumption 
would decline or increase somewhat, and the 
proportion of seizures would be slightly higher 
or lower. Using examples from 2008 and a pro-
portion of heroin seized of four per cent of an-
nual consumption, it is evident that even a chan-
ge of +/- 20 per cent in the number problem 
users or the annual quantity used would change 
the proportion of seizures by only one percenta-
ge point. Whether it is three, four or five per cent, 
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Heroin
While only 8.0 kg of heroin was seized in 2007, a 
number of medium-sized seizures of heroin were 
again made in 2008, amounting to a total of 55.2 
kg. However, at 1,147, the number of seizures 
was somewhat lower than in the previous year. 
Heroin was seized in 24 of the country’s 27 po-
lice districts, and more seizures were made in 
nine of the districts than in 2007. Oslo’s share of 
the seizures was 38 per cent. Seizures of heroin 
in 2008 only accounted for 4.8 per cent of the to-
tal number of drug seizures in Norway. By com-
parison, this proportion was as high as 20 per 
cent in 1998. 
Cannabis
The amount of cannabis seized in 2008 was 1,732 
kg, which breaks down into about 1,234 kg of 
hash (71%), 151 kg of marijuana (9%), 347 kg of 
Table 13 shows the changes in the number of sei-
zures during the period 2003 to 2008. Figure 14 
shows the market share in 2008 for the most 
common substances.
Figure 14: Market share for different drugs in 2008. 
Number of seizures. Percentage.
Cannabis
BZD
Heroin
Amph/methamphetamin
Cocaine
Ecstasy
Painkillers
Others
44,5
4,8
14,6
21,7
3,6
1,3
3,9
5,2
Source: Kripos
Table 12: Large drug seizures in 2007 and 2008.
Drug type Number of paragraph 3 cases 2007 Number of paragraph 3 cases 2008
Amphetamine and methamphetamine 28 (seizures over 3 kg ) 14
Cocaine 6 (seizures over 3 kg ) 4
Ecstasy 2 (seizures over 15,000 tablets) 0
Cannabis 1 (seizures over 80 kg ) 3
Heroin 1 (seizures over 0.75 kg ) 16
Benzodiazepines 0 1
Total 38 38
Source: Kripos
Table 13: Number of seizures in the period 2003-2008 broken down by some types of drugs*.
Drug type 2003 2004 2005  2006 2007 2008  % change 2007-2008 
Cannabis 10,397 10,097 10,128  11,221 9,952 10,591 + 6.5%
Amph/methamph 5,218 4,933  5.361      5,819 5,507 5,161 - 6.1%
Heroin 1,709 1,399  1,151 1,087 1,204 1,147 - 4.6%
Benzodiazepines 4,700 4,358  3,929 4,551 4,088 3,490 - 14.5%
Painkillers/ opioids 1,216 1,146  1,319 1,161 959 936 - 2.4%
Cocaine 504 464 685 726 909 854 - 6.0%
Ecstasy 405 452 341 411 421 310 - 25.4%
LSD 31 30 34 28 13 15 + 15.3%
GHB 120 28 46 65 163 134 - 18.4%
Psilocybe mushrooms 89 77 75 82 77 54 - 29.8%
*Some figures for 2003-2007 have been adjusted. 
Source: Kripos
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In 2008 as in previous years, seizures were made 
of tablets containing amphetamine, but the pro-
portion is marginal compared with powder 
forms of the drug. Of illegally manufactured ta-
blets with the same logo as ecstasy, 626 tablets 
were seized in seven seizures. 
Cocaine
In 2008, 76.8 kg was seized in 854 seizures. As in 
2007, cocaine was seized in 26 of the country’s 27 
police districts, but there are relatively big differ-
ences between the districts. In Oslo, the number 
of seizures declined by 17 per cent, while Bergen 
registered an increase of 63 per cent. Kripos does 
not distinguish as a matter of routine between 
cocaine hydrochloride and cocaine base 
(‘crack’).
Ecstasy 
In 2008, around 31,000 tablets and over 0.5 kg of 
powder containing ecstasy were seized in 310 
seizures. Seen from a historical perspective, these 
are small quantities, and the number of seizures 
has not been as small for ten years. The decline 
in the number of seizures from 2007 is all of 25 
per cent. Again in 2008, two large seizures (a to-
tal of 19,410 tablets) explain most of the amount 
seized.
BZD
A total of 311,366 tablets and 1.8 kg of active 
agents were seized in 3,490 seizures. Demand for 
this type of medicinal drug appears to remain 
large on the illegal market. Looking at seizures of 
tablets in 2008 exclusively, there is a clear decline 
cannabis plants (20%) and 0.011 kg of cannabis 
extract. One seizure of 401 kg of hash dominated 
in 2008.
The number of cannabis seizures, 10,591, con-
sists of about 82 per cent hash, 16 per cent mari-
juana and 2 per cent cannabis plants. The pro-
portion of hash on the market is thus approaching 
the same level as before 2007, almost 90 per 
cent.
Many cannabis plantations, some of them large, 
were also uncovered in the first six months of 
2008 (Table 14). 
Table 14: Cannabis plants – number of seizures and 
quantities seized in 2008. 
First half-year 
2008
Second half-
year 2008
Amount 324.5 kg 22.5 kg
Number of seizures 126 91
Source: Kripos
Amphetamine/methamphetamine
A total of 363.1 kg was seized, consisting of ap-
proximately 260 kg of amphetamine and 103.1 
kg of methamphetamine. The largest ever seizure 
of amphetamine in Norway, 112.3 kg, was made 
in 2008. This exceeded the previous record from 
1998 by 98.3 kg. Based on the number of seizures 
and verified10 analyses, the proportion of meth-
amphetamine once again increased significantly 
in relation to amphetamine (Table 15). See also 
chapter 12. 
10 A number of seizures of amphetamine have not been verified. 
Several of them probably contain methamphetamine. 
Table 15: Propotion of seizures of methamphetamine in relation to amphetamine. 1999–2008. 
Year 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
% Methamphetamine 1.3% 1.8% 6.2% 10.8% 15.4% 21.1% 22.0% 26.0% 35.3% 43.6% 
Source: Kripos
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doses in 15 seizures. Since LSD is easy to con-
ceal, however, we cannot exclude the possibility 
that the seizure statistics do not reflect the actual 
situation.
Psilocybe mushrooms 
The substance psilocybin has been included on 
the list of narcotic substances since 1971, but it 
was not until 2004 that all mushrooms contain-
ing psilocybin were regulated. It is mostly Psilo-
cybe cubensis and Panaeolus Cyanescens that 
have been registered in connection with impor-
tation. Although these mushrooms have never 
figured prominently in the statistics, Kripos does 
receive some information that these hallucino-
genics are still of interest as drugs. Among other 
things, the customs service and the police make 
seizures of cultivation media and spores from 
mushrooms containing psilocybin.
Other hallucinogenic drugs
A number of psychoactive substances were 
seized in several cases, first and foremost sub-
stances with a hallucinogenic effect, both sub-
stances that are included on the list of narcotic 
substances and substances not classified as nar-
cotics. These include: PCP, DOET, DOB, DOM, 
DMT, 2,5-dimethoxy amphetamine, 4-chlorine-
2,5-dimethoxy amphetamine, DPT, 5-MeO-
DIPT and piperazine derivatives. 
In the latter category, 1,(3-chlorphenyl)piperazi-
ne or mCPP should be emphasised. It first ap-
peared as a tablet in 2005, the same year as the 
largest single seizure was ever made in Oslo 
(10,030 tablets). mCPP, which is not yet on the 
Norwegian list of narcotic substances, has no in-
dustrial or medicinal application. The tablets are 
usually colourful and have the same logo as tra-
ditional ecstasy tablets.
Psychoactive plants and plant parts that are not 
classified as drugs are regularly seized on the 
grounds that their importation is not normally 
permitted. Much of this traffic is probably the re-
sult of information and offers on the internet. 
Kripos has registered in particular seeds of Argy-
reia nervosa (Hawaiian Baby Woodrose), Salvia 
in both the number of seizures and the number 
of benzodiazepine tablets. However, the picture 
is rather different for seizures of active agents. 
The explanation for this is the substantial seizure 
of pure phenazepam and illegally-manufactured 
tablets containing fenazepam made in one coun-
ty (Nord-Trøndelag). In addition to 28,580 tab-
lets containing 1.6 mg of phenazepam, seizures 
were made of 1,756 g of phenazepam with a pu-
rity of 87 to 90 per cent. Based on a medicinal 
dose of 1 mg, this one seizure corresponds to 
over 1.5 million tablets. Phenazepam is a Russian 
benzodiazepine that is not in medicinal use in 
Norway. 
Painkillers, medicinal drugs classified as 
narcotics
A total of 11,147 tablets were seized in 936 sei-
zures. Both the quantity and the number of sei-
zures has thus declined somewhat. There were 
no major seizures of these medicinal drugs in 
2008. Several of the cases involved the illegal im-
portation of such medicinal drugs via internet 
shopping, but the number of tablets in each sei-
zure is relatively small. Based on the number of 
seizures, buprenorphine (Temgesic, Subutex and 
Subuxone) predominates, but the seizures are 
generally small. More tablets containing codeine 
were seized than any other substance. 
GHB
Thirty-six litres of GHB were seized in 134 sei-
zures in 2008. Even if we include seizures of the 
industrial chemicals GBL and 1.4-butandiol, 
substances that are not included on the Norwe-
gian list of narcotic substances, the figures are 
deemed to be small, at 174 seizures in all, com-
pared with other depressants. However, the risk 
of being detected can be smaller than for other 
substances. Since the appearance and effect of 
GHB and alcoholic beverages are similar, we 
cannot exclude the possibility that the seizure 
statistics do not reflect the actual prevalence of 
the drug. 
LSD
Very few seizures of LSD are made annually, both 
in terms of number and quantity. In 2008: 245 
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variation in purity from seizure to seizure. Para-
cetamol, caffeine and other intoxicating substan-
ces (benzodiazepines) are also found in relatively 
many seizures. 
For hash, the average THC purity was around se-
ven per cent; however, the results of measure-
ments vary greatly. Based on the high number of 
hash seizures in Norway, there are therefore 
grounds for arguing that the average THC con-
tent in all types of hash seizures has not changed 
significantly. There was some focus on the THC 
content in connection with the discovery of rela-
tively large cannabis plantations in 2008. A total 
of 150 quantitative measurements of THC were 
carried out, both for whole plants and for isola-
ted top shoots. Whole plants usually contained 
three to seven per cent THC, and isolated top 
shoots usually 11 to 19 per cent. In one case, ap-
proximately 4 kg of isolated top shoots with a 
THC content of 22 per cent were seized, i.e. abo-
ut three times more than in traditional hash. This 
is becoming more and more common in large 
parts of Europe. 
The average purity of amphetamine in 2008 is es-
timated to be roughly 34 per cent and 39 per cent 
for methamphetamine. This is somewhat lower 
than has been registered in recent years, but the-
re is still considerable variation. 
The cocaine content in seizures has fallen steadi-
ly, from more than 70 per cent over ten year ago 
to an average of 37 per cent in 2008. Cocaine hy-
drochloride of high purity was also seized in 
2008. Fenacetine is still used as an additive. 
For ecstasy, the proportion of MDMA in the sei-
zures has declined significantly in relation to 
previous years and been replaced by other sub-
stances, such as chlorphenyl piperazines, but also 
by substances not classified as narcotics (Kripos 
2009). 
divinorum, Peganum harmala, seeds of peyote 
cactus and peyote cactus containing mescaline.
10. 4  Price of illicit drugs at  
retail level 
The latest pricelist from the police, from October 
2008, was presented in NR 2008:
For smaller quantities, the price level seems to 
have largely remained stable for most of the ty-
pes of drugs since the last overview produced by 
the police in autumn 2006. In nominal terms, 
prices have probably fallen slightly rather than 
the opposite. The most striking development is 
that the price of cocaine appears to have fallen 
for typical sales doses. In 2006, the price for half 
a gram of cocaine was estimated to be approxi-
mately EUR 62.5 (NOK 500), while in 2008 it 
was approximately EUR 37.5 - 50 (NOK 300-
400). By comparison, the market price for heroin 
in 2008 was estimated to be EUR 62.5 (NOK 
500) for 0.5 grams and EUR 25 - 37.5 (NOK 200-
300) for 0.2 grams. Cocaine is still expensive in 
relation to amphetamine. The price level for one 
gram is more than double the price level for 
amphetamine, and the differences seem to be 
even greater for large quantities. The prices for 
ecstasy, GHB and LSD are stable, while the price 
level for Rohypnol (per tablet, 100 mg) on the il-
legal market seems to have fallen since 2006. 
Chapters 11 and 12 contain some price estimates 
for user doses of cannabis and amphetamines 
that differ in part from the overview for 2008. In 
addition, the prices of illegal drugs must natu-
rally be treated with considerable caution. 
10.5  Purity/potency/composition 
of illicit drugs and tablets
See data in Standard tables 14 and 15.
The average purity of heroin has been relatively 
stable in recent years, and in 2008 it was calcula-
ted to be 31 per cent. However, there is still great 
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Selected issues
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etnamese backgrounds. There are many indicati-
ons that these production facilities were establis-
hed by persons who were familiar with this 
method of producing marijuana from other co-
untries, but who were less familiar with Norwe-
gian conditions. One of the reasons why many of 
these ’farms’ were discovered was that they were 
often located in small towns or out of the way 
locations. Thus, they often quickly attracted the 
attention of the locals by keeping the lights on at 
all hours, plus the fact that the windows steamed 
up. Another question is the sale of the marijuana. 
How were they supposed to sell such large 
quantities (in the Norwegian context) as disco-
vered here without drawing attention to 
themselves?
The fact that these ’farms’ emerged at the same 
time, that they were run in the same way by peo-
ple from the same ethnic backgrounds, and on 
such a scale, suggests that they were part of a lar-
ger and more organised scheme. This method is 
otherwise well-known from countries such as 
the Netherlands, Canada and England (Duyne 
and Levi 2005). Because of these ‘farms’, the total 
number of seizures of plants increased dramati-
cally in 2007 and in the first six months of 2008 
(Chapter 11.2.3). 
11.1.2  Consumer markets share of  
different cannabis products
In Norway, the use and sale of cannabis is domi-
nated by hash. Measured by the number of sei-
zures, marijuana only accounts for 10 to 15 per 
cent (see Chapter 10.3.2). This proportion can 
also be an indication of the use of the drug. 
11.1.3  Distribution of cannabis  
at national level 
The police often claim that the cannabis market 
(i.e. the hash market) has been dominated by a 
few major players who have been active for sev-
eral decades. A few people are said to have kept 
Paul Larsson, professor, the Norwegian Police 
University College
11.1 Markets 
11.1.1 Cannabis domestic production 
The hash that is used in Norway is mostly pro-
duced abroad. In recent years, the hash has 
mainly come from Morocco. The police estimate 
that between 80 and 90 percent comes from 
there. In addition, there are individual cases in-
volving hash and marijuana from Thailand and 
Pakistan. On the other hand, there is reason to 
believe that a large proportion of the marijuana 
that is used in Norway is produced domestically. 
This type of production has been going on for a 
long time. The scale of the production varies 
greatly, from those who cultivate marijuana for 
their own use or for friends and acquaintances to 
those who cultivate the drug with the intention 
of selling it. Small-scale home production in 
lofts, basements or outdoors in flower beds is 
relatively widespread, as proved by frequent me-
dia reports about police seizures of this type. 
From autumn 2007 onwards, the police disco-
vered a number of marijuana plantations in pri-
vate homes. This was something new in the Nor-
wegian context. Few people had anticipated 
cultivation on such a scale taking place in large 
areas of Eastern Norway. Marijuana plantations 
had been uncovered previously, but not of the 
type found in these cases. The method is well-
known abroad. You convert a house or an apart-
ment into a production facility by installing wa-
tering systems and heating and lighting 
equipment. Usually, these houses were rented, 
and they were virtually gutted as a result of the 
installations. 
The players were also largely unknown in the 
Norwegian context. Most of them were from Vi-
11. Cannabis markets and production 
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do so a few times and that they are also involved 
in other types of crime. 
Smuggling can be roughly divided into three 
parts. There are a relatively high number of peo-
ple who smuggle for their own or for their fri-
ends’ use. They import small quantities. In an 
intermediary position, we find those who smugg-
le some tens of kilos. Many of the intermediate-
level players are involved in several types of cri-
mes, and importing hash is just one of many 
other offences. The degree of professionalism is 
fairly limited. In recent years, there have been a 
number of cases involving large quantities where 
several hundred kilos of hash have been impor-
ted. In many cases, professional carriers and co-
uriers have been used. Importation on this scale 
can often be linked to established organised 
gangs. Some have been involved in importation 
for many years, but there are also a number of 
opportunists with a more short-term perspecti-
ve. Large-scale importation of hash can be a pro-
fitable form of smuggling (Pedersen, 2009). 
This flexibility in the importation of cannabis 
means that the market is open to many players. It 
is highly adaptable and will therefore be relati-
vely unaffected if the police or customs service 
manages to catch one or more major players. It is 
interesting to note that, in many cases, hash 
smuggling is combined with the smuggling of 
pills, amphetamine and ecstasy. On the other 
hand, there seems to be almost no connection 
whatsoever between those who are involved with 
heroin and those involved with hash. People who 
smuggle spirits very seldom have anything to do 
with hash. 
11.1.4 Cannabis prices 
The price level for a normal sales dose of hash on 
the street has been stable for many years, at about 
EUR 12.5 (between 0.7 and 1 gram). This means 
that the price of hash has fallen relatively speak-
ing. This price has also remained stable regard-
less of availability. Whether there has been a dry 
spell or a flood on the market has had little effect. 
All this suggests that it has not been a market 
price, but a price based on tradition and custom. 
the business going – with the exception of peri-
ods spent in prison – since the 1970s. It is a well-
known fact that these persons have connections 
with established organised criminal gangs that 
are involved in several types of crimes. Among 
other things, some of the largest seizures are 
linked to persons affiliated to motorcycle clubs, 
organised gangs and the so-called armed rob-
bery milieu.
It is difficult to provide a simple description of 
the players involved in the smuggling and selling 
of hash in Norway, as it seems to be a highly fle-
xible market that has ties to several quite distinct 
milieus. We have a fairly good overview of street-
level sales. Knowledge about smugglers and cou-
riers is also relatively extensive. On the other 
hand, we know little about the so-called ringlea-
ders and wholesale dealers. The question, of co-
urse, is whether there are any clear ringleaders. 
There are many indications that there are few 
links in the chain between importation and the 
direct sale of hash to users. Price estimates sug-
gest that sellers buy from persons who themselves 
have bought the drug from importers, or that 
there is one more link in the chain (Larsson, 
2006). 
The cannabis market is often linked to particular 
ethnic groups. It is assumed that Moroccans have 
come to play an important role in several Euro-
pean countries. In Norway, importation and dis-
tribution seems to be a largely multi-ethnic busi-
ness. It is common to see teams of smugglers 
composed of persons from Norwegian, Asian 
and African backgrounds. Street-level sales have 
in recent years largely been dominated by groups 
of people from immigrant backgrounds. 
There are also clear differences between those 
who smuggle hash for their own use or for fri-
ends and acquaintances, those who operate on a 
small commercial scale and those who import 
large quantities. Most run a type of small-scale 
operation, on a kind of ‘cottage industry’ basis 
(Eck and Gersh 2000). There are many indicati-
ons that those who import large quantities only 
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was NOK EUR 2,500 to 4,375 (NOK 20,000 – 
35,000).
Typology of retail outlets for cannabis sale
Most sales are made between friends and ac-
quaintances and in networks of which the police 
do not have a full overview. There are also street-
level sales on a considerable scale, especially in 
Oslo, where the focus for some time has been on 
the open street market. Over the years, the sales 
market has changed location several times in 
Oslo city centre. In recent years, the sellers have 
mostly been teenage boys from immigrant back-
grounds. Many of them are asylum seekers, often 
without residence permits in Norway (Sandberg 
and Pedersen, 2006). Some of the sales also take 
place in connection with nightspots and pubs. 
Little is known about the market for marijuana. 
An open market hardly seems to exist, and to the 
extent that marijuana is available, it is sold among 
friends and in networks. 
11.2 Seizures
11.2.1  Supply reduction organisation and 
activities
Since the turn of the millennium, the number of 
seizures of hash has varied somewhat, but it has 
mainly been around 10,000 per year (see statistics 
in Chapter 10.3.1). This tells us that the average 
seizures are small. In 1990, the average was 54 
grams, while it was 220 grams in 2004. During the 
period 2000 to 2005, the number of big seizures 
increased significantly. This is confirmed by a 
number of cases involving seizures of 300 to 500 
kilos of hash. Seizures of that size were very rare 
before 1995. In recent years, big (by Norwegian 
standards) seizures of this kind have declined. The 
biggest single seizure in 2008 was 400 kilos, how-
ever, while the biggest in 2007 was 169 kilos. 
The explanation for this development is somew-
hat uncertain. There are many indications that 
the situation up until around 2005 was characte-
rised by a great willingness among smugglers to 
take risks, and large quantities were imported. At 
the same time, however, it seems as if the police 
If this is correct, it is very interesting in itself as it 
differs from the markets for other drugs that 
seem to be chiefly governed by supply and de-
mand. 
However, an unexpected change took place in 
summer 2009, when the street price of hash in 
Oslo fell to about EUR 6.2511 (NOK 50) for 0.7 to 
1 gram. The ordinary price of EUR 12.5 (NOK 
100) suddenly no longer applied, and it was pos-
sible to buy cheap hash. Since autumn 2009, the 
price has been back at its previous level of EUR 
12.5, and at times even higher. It has been said 
that the hash was often of relatively poor quality, 
but this had not affected the street price before. 
The sellers were often generous with the quanti-
ties. We can speculate about the explanation for 
these price variations. There are many indicati-
ons that increased availability of hash could be 
an explanation for the low price in summer 2009. 
According to the police, large quantities are be-
ing smuggled by professional carriers, but in-
creased availability alone cannot explain the pri-
ce drop. Previously, the price elasticity of hash 
has proved to be poor. It has been suggested that 
Moroccans have now established themselves as 
major players in import and sales, which means 
that it is possible to reduce both the number of 
links and the price. As an explanation for why 
prices have again risen in autumn 2009, it is ar-
gued that increased border controls in Gibraltar 
and campaigns by the Moroccan authorities have 
influenced supply and the price level. 
Buying large quantities quickly reduces the price. 
If you buy 10 grams, the price will often be 
halved, and if you buy, for example, one kilo, de-
pending on the quality, the price may be EUR 3.1 
to 3.8 per gram (NOK 25 to 30). The price level 
per kilo also seems to have declined from 2005 
to 2008 in real terms. For example, the estimated 
price for one kilo of hash in 2008 was EUR 3,125 
to 3,750 (NOK 25,000 - 30,000), while in 2005 it 
11  Conversion rate 1 EUR= NOK 8.00
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to medium-sized cases (10 to 99 kilos), of which 
four of eleven involved hash from the Nether-
lands, two from Spain, two from Norway and 
one each from Denmark, Thailand and Sweden. 
Although the figures are not representative, they 
nevertheless indicate that most of the hash is 
bought in the Netherlands. There are many indi-
cations that, among other things, this is related 
to the good contact that exists with middlemen 
and suppliers in the country. 
Although transport by heavy goods vehicles se-
ems to be most common way of importing large 
quantities, people are very inventive when it co-
mes to smuggling methods. Norway has a long 
coastline, and a great deal is imported by ferry or 
boat. In addition, both large and small quantities 
are smuggled in many different ways, such as by 
plane, as ‘legal’ goods, in the mail, in containers, 
in camper vans and passenger cars (Larsson, 
2006). It appears that the vast majority of the 
hash goes via Oslo and is then spread to other 
parts of the country. The reason for this may be 
that most organised criminal networks are based 
in the Oslo area. 
Large consignments have been brought in on 
small boats and stored temporarily in the island 
archipelago, as in the classic descriptions of the 
smuggling of spirits in the 1920s. However, the 
most common mode of transport is still by ferry 
or by road, depending on the size of the ship-
ment. There are many semi-professional players 
who drive all the way to Amsterdam by car, whe-
re several persons, typically five or six, make up a 
team and where the quantities are somewhat lar-
ger. Among the more professional players are 
forwarding companies that hire out heavy goods 
vehicles that cannot be scanned, in addition to 
drivers. These services are not cheap and they 
can eat up a substantial part of the profit. Of co-
urse, the advantage is that it is possible to have 
the goods delivered relatively safely to central 
areas of Eastern Norway, while being less at risk 
if the shipment is stopped. 
and customs service became better at tracing 
large quantities, for example through the use of 
new surveillance methods. During the last seven 
to eight years, the police have been allocated 
substantial funds to combating organised crime. 
Fighting drug crime has been a key element in 
this context. This also means that bigger cases, 
so-called paragraph three cases12, are given prio-
rity. The number of such cases has increased sig-
nificantly, from 55 in 2000 to 122 in 2007. There 
are no data about how many of these were rela-
ted to cannabis. 
11.2.2  Smuggling routes and modus 
operandi
A study of cannabis smuggling (Larsson 2006, 
2009) showed that most of the seizures of can-
nabis on its way into the country by the police 
and customs, took place between Stavanger on 
the west coast, via key ports on the south coast of 
Norway to Oslo via Østfold and the Swedish bor-
der to Kongsvinger.
The smuggling routes are relatively simple. The 
hash is usually transported by boat from Moroc-
co to Spain, some of it directly to other ports, for 
example in the Netherlands. From Spain, it is 
usually transported via the Netherlands to Nor-
way, normally on the E6 motorway from Den-
mark via Sweden and Svinesund. Large consign-
ments are either bought in the Netherlands or in 
Spain, very rarely in Morocco.13 
The Netherlands stands out as a main country in 
the research material, which comprises 34 court 
judgments, mainly convictions for large quanti-
ties. Of 15 cases involving more than 100 kilos of 
hash, the hash was bought in the Netherlands in 
nine of them, while three were directly linked to 
Spain. The picture is equally clear when it comes 
12 Applies to cases pursuant to the General Civil Penal Code sec-
tion 162 third paragraph, which concerns the most serious drug 
crimes. 
13 Even though the price level in Morocco is very low, the risk of 
being arrested as a ‘white male’ is considered to be high. Mo-
reover, it must be assumed that very few people have contacts 
among suppliers in the country, which is crucial for a smuggler 
(Gross 1992).
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11.3 Offences
Police statistics do not distinguish between dif-
ferent types of drugs. In the registration context, 
a distinction is drawn by the size of the ship-
ments that can be linked to defendants. Pursuant 
to the General Civil Penal Code section 162, a 
distinction is drawn between so-called paragraph 
one, paragraph two and paragraph three cases. 
The first paragraph covers small shipments, the 
second paragraph applies to medium-sized 
quantities, while the third paragraph applies to 
the largest quantities. The limit for cannabis is 80 
kilos, a limit that was set following a case in 
which 80 kilos of marijuana were smuggled to 
Norway from Thailand. Use and possession of 
cannabis is mainly covered by the Act relating to 
medicines. 
The seizure figures provide an indication of how 
large a volume the cannabis cases account for of 
the total number. Around 10,000 seizures of can-
nabis a year – of which most are minor seizures, 
typically use and possession – mean that a sub-
stantial proportion of registered drug crimes are 
hash cases. In 2007, approximately 20,000 formal 
complaints were brought pursuant to the Act re-
lating to medicines section 31, and around 17,500 
paragraph one cases pursuant to the General Ci-
vil Penal code section 162. It is not known how 
many of these concerned hash. The seizure figu-
res are generally difficult to compare, because the 
persons reported are typically reported for seve-
ral crimes at the same time, for example both use 
and possession. 
11.2.3 Seizures of plantations 
Seizures of cannabis plants increased strongly in 
2007 and 2008 compared with previous years 
(119 kilos/ 207 seizures and 347 kilos/ 217 sei-
zures). This was mainly due to the discovery of 
cannabis plantations. So far, around 50 such 
plantations have been discovered. According to 
Kripos, the number of “cannabis plantations” 
will probably be greatly reduced in 2009.
11.2.4  Breakdown of cannabis seizures by 
product and by amount seized 2008 
The amount of cannabis seized in 2008 was 1,732 
kg, which breaks down into about 1,234 kg of 
hash (71%), 151 kg of marijuana (9%), 347 kg of 
cannabis plants (20%) and 0.011 kg of cannabis 
extract. No detailed information is available 
about the breakdown of seizures by weight and 
type of product, but Table 16 provides an illus-
tration of the thirteen biggest individual seizures 
made in 2008 and the type of cannabis involved.
Table 16: Individual seizures of cannabis in 2008 by 
amount and type of product.
Police district Amount Product
Oslo 400.9 kg Hash
Hedmark 145.4 kg Hash
Oslo 121 kg Hash
Oslo 39.1 kg Hash
Hedmark 38.4 kg Marijuana
Follo 26.7 kg Cannabis plants
Oslo 25.6 kg Hash
Gudbrandsdal 22.5 kg Cannabis plants
Hedmark 21.4 kg Cannabis plants
Follo 21.3 kg Hash
Søndre Buskerud 21.2 kg Cannabis plants
Oslo 19.7 kg Hash
Romerike 14.9 kg Cannabis plants
Source: Kripos
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amine is used. This may be the reason why 
methamphetamine has achieved such an impor-
tant place in Norway. However, many users, and 
perhaps also dealers, do not know whether they 
are dealing with amphetamine or methamphet-
amine. While some experienced users claim to 
’know when they are given good or bad drugs’, it 
has not been confirmed that this indicates actual 
recognition of methamphetamine rather than am-
phetamine or whether it refers to other phenom-
ena (such as purity), or whether it is simply a 
myth.
Surveys carried out among the general populati-
on do not contain separate questions about the 
use of methamphetamine. As regards more pro-
blematic use of amphetamine, frequency may be 
an indicator. Among young adults aged 21 to 30, 
three per cent said that they had used ampheta-
mine 5 to 25 times, while three per cent had used 
the drug more than 25 times (overall proportion 
from surveys carried out in 2002 and 2006, see 
chapter 2.3). 
The use of methamphetamine among men who 
have sex with other men has been explored in a 
number of publications (16). American surveys 
show that this group is probably overrepresented 
among users, and that it is associated with other 
types of risk behaviour such as sex with unknown 
partners, unprotected sex and thereby with an 
increased risk of HIV transmission (17). Some 
anecdotal reports exist of such use among mem-
bers of Norwegian gay club scenes (18). However, 
we do not have surveys from Norway correspon-
ding to those from the USA, and it is important 
to keep in mind that, in practice, we are dealing 
with two different substances used in the two co-
untries: smoking of ’crystal meth’ in the USA and 
snorting or injecting powder in Norway. 
Jørgen G. Bramness, Director of science / professor, 
Norwegian Centre for Addiction Research -SERAF
12. 1 Introduction
Norway is on the outskirts of Europe, not just geo-
graphically but perhaps also in terms of patterns 
of drug use. It has been reported in recent years 
(1, 2) that more amphetamine than cocaine is 
used in Norway and that methamphetamine has a 
large and increasing share of the illegal market for 
central stimulants. Others have claimed that, un-
like in the USA (3, 4), Australia (5) and Asia (6), 
methamphetamine is not much used in Europe 
and that most of the use takes place in Central Eu-
rope based on production in the Czech Republic 
and Slovakia (7). In the following, we will use var-
ious data sources to study the prevalence of am-
phetamines (amphetamine and methamphet-
amine) and the relationship between the two 
substances in Norway in recent years.
12.2  Epidemiology of  
amphetamine and  
methamphetamine use
12.2.1  Trends and patterns of (meth)
amphetamine use 
In Norway, both amphetamine and methamphet-
amine are sold as white powder. In large areas of 
the world, methamphetamine is manufactured 
and sold as crystalline methamphetamine (‘ice’). 
This form of the drug is rarer in Norway. The 
powder is usually taken orally, snorted or injected, 
while the crystalline form can be smoked. Injec-
tion is more common in Norway (and Scandina-
via) than in other countries where methamphet-
12.  Problem ampthetamine and  
methamphetamine use, related  
consequences and responses
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cohol (the Road Traffic Act section 22 concer-
ning driving under the influence). Every year, 
the police stop and test several thousand drivers 
suspected of driving under the influence (see 
also Chapter 9.2.1). On suspicion of other sub-
stances than alcohol, the person is question is 
brought before a doctor who takes a blood sam-
ple and performs a clinical examination (9, 10). 
For years, this data set has been a rich source of 
information about the use of medicinal drugs 
and narcotics (11, 12). Of course, there is a selec-
tion bias in this material in that it only includes 
those who drive and attract the attention of the 
police, but this bias has been constant for many 
years, and the data can nonetheless be used to 
shed light on developments over time.
The other source of data consists of urine samples 
from inmates in Norwegian prisons. Every year, 
around a thousand urine samples are taken from 
inmates in Norwegian prisons, partly as a matter 
or routine on admission and on return from le-
ave, partly on suspicion of use (Chapter 9.4). As 
certain rules apply to the taking of urine samples 
that may lead to sanctions, these samples are also 
subjected to the same analyses using forensic to-
xicological methods. The procedures mean that 
nor is this material without selection bias, but 
again the bias has been relatively constant over a 
number or years, which means that it is possible 
to look at developments over time.
The third source of data from NIPH consists of 
results from autopsies in which forensic toxico-
logical examinations have been performed post 
mortem. Between 1,500 and 2,000 such post 
mortem toxicological analyses are performed 
every year at NIPH. The National Institute of Pu-
blic Health is not the only institution that per-
forms such analyses in Norway, and, again, there 
could be selection bias, but like the other data, 
this material can also be used to observe de-
velopments over time. 
All analyses performed by NIPH are carried out 
using chromatographic methods that ensure a 
high level of sensitivity and specificity when de-
termining the use of different substances. It is 
Treatment demand for  
(meth)amphetamine use 
In the annual nationwide client mapping of treat-
ment and care facilities, information is provided 
about the two amphetamines combined (see 
Chapter 5.2.1). The proportion reporting meth-
amphetamine/amphetamine as the most used 
intoxicant on admission has increased over the 
last ten years from about five per cent to nine per 
cent. However, these are aggregated data that 
also include alcohol. Corrected for alcohol, the 
proportion reporting methamphetamine/am-
phetamine as the most used intoxicant was ap-
proximately 16 per cent in 2007, which is on a 
par with cannabis, but clearly behind heroin 
(37%) (personal communication Erik Iversen, 
the Bergen Clinics Foundation). 
Production sites and laboratories, origin of 
products and trafficking routes, precursors 
seizures. 
Information is scarce about the manufacturing 
of amphetamines in Norway. It is probably only 
small-scale production, at most. The most com-
mon smuggling routes are discussed in Chapter 
10.2. According to the customs service, most of 
the amphetamine and methamphetamine on the 
Norwegian market comes from illegal laborato-
ries in Poland and Lithuania. The largest quanti-
ties seized today, however, come from the Neth-
erlands and Poland, through Germany and 
Denmark and via Sweden. 
12.2.2 Epidemiological studies 
Material and method
The Norwegian Centre for Addiction Research 
– SERAF – has collected data for a study from 
four different bodies:
The National Institute of Public Health (NIPH)
Three types of data were collected from the Divi-
sion of Forensic Toxicology and Drug Abuse Re-
search at the Institute of Public Health for the 
period 2000 to 2008:
The first source of data consists of blood samples 
from cases in which the police suspected driving 
under the influence of other substances than al-
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well with reports from NIPH. In the same way as 
NIPH, Kripos also uses chromatographic meth-
ods of analysis that ensure a high level of sensi-
tivity and specificity. Not all seizures are analy-
sed, however. This means that the published 
figures are minimum figures. The data from Kri-
pos is from the period 1994 to 2008.
Emergency psychiatry
SERAF has carried out two surveys of emergency 
psychiatry services in Oslo: a pilot survey in au-
tumn 2003 (13) and a new survey in autumn 
2006 (unpublished data). All patients admitted 
during a specific period of time gave anonymous 
blood samples, and we used this material to shed 
light on the prevalence of amphetamine and 
methamphetamine in this group. Again, this 
sample is highly selective, as it consists of pa-
tients admitted to an emergency psychiatric de-
partment. This population is mainly dominated 
by acute psychoses characterised by uncontrolled 
behaviour and suicidality problems (14).
The Norwegian Institute for Alcohol  
and Drug Research (SIRUS)
Data from SIRUS are taken from the survey that is 
carried out twice a year at the central needle dis-
tribution facility in Oslo city centre. The partici-
pants are mainly injecting drug users. Those who 
come to the needle distribution facility probably 
belong to a more marginalised group than the av-
erage users of both opiates and amphetamine, and 
may represent the abject group of users. Data from 
this survey have been supplemented by Anne-
Line Bretteville Jensen at SIRUS.
12.2.3 Results
The National Institute of Public Health (NIPH)
Figures from NIPH and the three sources of data 
that constitute the material are presented in Fig-
ures 15-18. Here, the relative proportions of the 
samples that tested positive for amphetamine and 
methamphetamine are shown. Table 17 shows the 
total number of cases. For the period 2000 to 2008, 
the proportion of samples that tested positive for 
amphetamines was from 18 to 28 per cent in driv-
ing cases, from three to five per cent in the cor-
rectional services (urine samples) and from five to 
possible, for example, to distinguish between 
amphetamine and methamphetamine, and these 
substances can also be distinguished from other 
medicinal drugs (such as ephedrine), which 
would otherwise be a problem if semi-quantita-
tive methods were used (such as urine sticks). 
Since methamphetamine to some extent meta-
bolises into amphetamine, amphetamine will 
usually also be present when methamphetamine 
has been used. All samples in which methamp-
hetamine was found were therefore considered 
to be methamphetamine samples, regardless of 
how much amphetamine was found. This has 
probably led to an overestimation of the preva-
lence of methamphetamine cases, since, in some 
cases, there was so much amphetamine present 
in the methamphetamine sample that it could 
not be the result of using methamphetamine alo-
ne, i.e. amphetamine must have been used as 
well. However, we have kept these figures to av-
oid underestimating the proportion of met-
hamphetamine, at the same time as we want to 
avoid giving the impression that the total num-
ber of cases is higher than it actually is. If the 
number of cases in each category had been co-
unted, the total number of cases would have been 
too high because many samples contain both 
amphetamine and methamphetamine.
The National Crime Investigation Service (Kripos)
The seizure statistics from Kripos, particularly 
concerning the number of seizures, can be im-
portant in relation to describing how the situa-
tion in Norway has developed (see data in Chap-
ter 10.3.2). The quantity of narcotics seized does 
not give as accurate a picture of the activity in 
the drugs market, since large individual seizures 
will affect the statistics disproportionately. The 
number of seizures, however, will better reflect 
the situation in the user milieus. Since there is 
often a strong connection between the priorities 
of the police and efforts targeting user milieus 
and the number of seizures, the number of sei-
zures made during a year can vary greatly. The 
annual statistics from Kripos indicate the relative 
proportion of seizures of amphetamine and 
methamphetamine and the ratio between the 
two substances. These data have corresponded 
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SIRUS found an increase in the proportion repor-
ting that they had used amphetamine during the 
last month (59% compared with 68%). There was 
also an increase in the number of days that the 
amphetamine users reported having injected the 
drug (12.5 days compared with 16.6 days). 
Of those who reported use of amphetamine du-
ring the last month, 77 per cent reported also ha-
ving used cannabis in the same period (n=1,390), 
while 75 per cent reported injection of heroin 
and 20 per cent reported having used cocaine.
12.3  Treatment for  
(meth)amphetamine use
Treatment of amphetamine dependency and 
methamphetamine dependency is a relatively 
unexplored area. Amphetamine users are often 
difficult to reach with therapeutic measures and 
they often do not seek help themselves. The most 
tested non-pharmacological technique is contin-
gency management, which has proved to be ef-
fective. In addition, treatment with different 
pharmaceuticals, such as buporprione, stimu-
lants (modafinil and methylphenidate) and anti-
epileptic drugs, has been tested, but a summary 
of the literature shows a lack of good studies of 
effective pharmacological treatment options 
(19), and that treatment is largely dependent on 
non-pharmacological interventions. The use of 
naltrexone has yielded promising results in a re-
cent Swedish study, with respect to both actual 
use and perceived effect (20, 21).
Persons with amphetamine or methamphetami-
ne in the blood are strongly represented among 
those admitted for emergency psychiatric treat-
ment in Norway, and these substances are clearly 
the largest single group of drugs found among 
this group of patients (13). This corresponds well 
with what we know about the side-effects of 
amphetamine and methamphetamine use (8), 
even though the extent may be surprising. Most 
of the patients who were admitted for emergency 
psychiatric treatment had used a number of 
other substances. It is not known whether this 
eight per cent in autopsy cases. For all the catego-
ries, the proportion of methamphetamine of all 
the cases involving amphetamine has gone from 
being almost zero around the turn of the millen-
nium to as high as 69 per cent (Figure 15), 54 per 
cent (Figure 16) and 80 per cent (Figure 17), re-
spectively, of all cases in 2008. 
Kripos
Figure 18 shows the same development in the re-
lationship between amphetamine and metham-
phetamine as for the number of seizures. In 2000, 
methamphetamine only accounted for six per 
cent of the total seizures of the two drugs, in 
2008 the proportion was 44 per cent, and in the 
first six months of 2009 the proportion of sei-
zures was as high as 68 per cent (data from 2009 
are not shown in Figure 18).
Emergency psychiatry
One hundred patients were tested in autumn 
2003. In this group, 22 patients had amphetamines 
in their blood, urine or both, which is a sign of 
relatively recent use of amphetamines (13). Of the 
22 patients, 14 (63%) had used methamphet-
amine, while eight of the 15 (53%) whose blood 
tested positive had used methamphetamine. A 
screening of 300 patients in 2006 revealed that 41 
persons (14%) tested positive for amphetamine. 
In the 2006 survey, all the patients had used meth-
amphetamine.
SIRUS
The users who visited the needle distribution fa-
cility in Oslo city centre stated that they were un-
able to distinguish between amphetamine and 
methamphetamine when purchasing the drug. 
The self-reported data therefore include figures 
for the use of both amphetamines. The data are 
not presented in any table or figure. In the period 
1999 to 2008, SIRUS found that 63 per cent of 
the interviewees reported that they had used am-
phetamine during the last month (number of re-
spondents n=2,219). The average number of days 
of use during the last month was 14.5 (n=1,394). 
By splitting the responses into two five-year groups 
(group 1=1999 to 2003 vs. group 2=2004 to 2008), 
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hamphetamine has been the dominant drug for 
many years already, but that may be due to the 
fact that, because of our method, we underesti-
mate the incidence of amphetamine somewhat. 
This source of error probably increases in step 
with the exposure to the drugs. Thus, we see that 
the curves intersected first in autopsy cases, whe-
re most drugs are included, and last in prison ca-
ses, where the access to intoxicants is presumably 
lower. The figures from NIPH can nonetheless be 
used to confirm the almost linear increase for 
methamphetamine over a number of years.
In principle, we can envisage both supply and 
demand being contributory factors to such a de-
velopment. Some users claim to be able to distin-
guish between ’good and bad amphetamine’, 
implying that they know whether they have ta-
ken amphetamine or methamphetamine. The 
survey from the needle distribution facility, 
however, suggests that this is not common know-
ledge and that those buying drugs do not emp-
hasis this. This is supported by reports from the 
courts (Jørg Mørland NIPH, personal correspon-
dence), in which defendants in various cases do 
not know whether they have taken amphetamine 
or methamphetamine, and where biological tests 
show which of the drugs was taken. 
Despite the fact that defendants in such cases 
may have an interest in appearing ignorant of 
this difference, there is reason to believe that we 
must look to the supply side to find the explana-
tion for the development. Similarly, it is possible 
that those who claim to be able to distinguish 
between ’good and bad amphetamine’ wish to 
appear more experienced and knowledgeable 
than they actually are. Moreover, the purity of 
the two types of amphetamine will also vary (see 
Chapter 10.5), which may be the explanation for 
the difference between good and bad ampheta-
mine. In other words, we cannot assume that de-
mand is the reason why we have seen such a dra-
matic shift in which of the two drugs is found. 
There is reason to believe that the trend has more 
to do with supply. New drug trading patterns 
have developed in step with the liberalisation of 
was part of multiple use or whether depressants 
had been taken to end the period of intoxication. 
However, the high number of depressants may 
indicate that at least some were taken to end a 
period of drug abuse. When this period ended in 
psychosis and admission to emergency psychia-
tric treatment, it is an indication that we are dea-
ling with members of a selected population who 
have been unsuccessful in their attempt to end a 
period of abuse in a constructive manner. 
Whether this has been made more difficult by 
the fact that we are dealing with methampheta-
mine is unknown, but we observe that all pati-
ents with amphetamine in the blood at the time 
of the last survey had used methamphetamine.
12.4 Discussion 
None of the data sources used can give a com-
plete picture of the prevalence of amphetamine 
and methamphetamine use in Norway. Instead, 
the data sources represent different signs of the 
use. However, the main findings indicate that 
there has been an increase in the use of amphet-
amines in Norway for many years and that this 
increase has mostly concerned the use of meth-
amphetamine. There is reason to believe that 
methamphetamine is currently more used than 
amphetamine in Norway. Thus, the survey repre-
sents something of a contrast to previous reports 
that indicate little use of methamphetamine in 
our part of Europe (7), while it confirms previ-
ous reports from EMCDDA indicating that Nor-
way is the country in Europe with the quantita-
tively largest and highest number of seizures, and 
where the problems associated with metham-
phetamine can also be substantial (1, 2).
The most remarkable finding in the present sur-
vey is that most of the amphetamine used now 
appears to be methamphetamine. The increase 
in the proportion of methamphetamine has been 
a linear trend over many years in all the available 
data sources. As regards seizures, 2009 appears 
to be the year when the number of methamphe-
tamine seizures exceeds that of amphetamine. 
NIPH’s laboratory analyses indicate that met-
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Future studies will have to follow the develop-
ment of amphetamine use in the population and 
the proportion of methamphetamine users by 
utilising different sources of data. It is also neces-
sary to find out whether the available Norwegian 
figures show a Norwegian trend only, or whether 
the same developments are also taking place in 
the other Scandinavian countries and possibly in 
Russia. Similarly, it will be important to study 
different negative consequences.
Figure 15: Findings of amphetamine and metham-
phetamine in cases of suspected driving under the 
influence of non-alcoholic drugs where forensic 
toxicological analyses have been performed. In 
numbers 2000–2008.
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Figure 16: Findings of amphetamine and metham-
phetamine in cases from the criminal justice system 
where forensic toxicological analyses have been 
performed. In numbers 2000–2008.’
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border controls in Europe, and there is reason to 
believe that the most important explanation for 
the shift from amphetamine to methampheta-
mine as the predominant substance in Norway is 
new producers and importers in the market, pos-
sibly production in the Baltic countries (2).
The combination of users not knowing whether 
they are using amphetamine or methampheta-
mine, the fact that the use of amphetamines is 
increasing and that methamphetamine has be-
come the predominant amphetamine on the 
Norwegian market means that there is a clear 
danger that we will see more negative consequ-
ences of use in Norway than in many other co-
untries. The available road traffic data and data 
from psychiatric services are only two examples. 
Problem users of amphetamine and methamphe-
tamine are not ’loyal’ users who only stick to one 
drug. This is confirmed by data from, for example, 
the needle distribution facility. In part, they are 
addicted to more than one substance, and in part, 
they use a number of different pharmaceuticals to 
calm down after having used amphetamines for 
several days. This is a typical finding in the survey, 
which includes psychiatric patients who, among 
those with amphetamine or methamphetamine in 
their blood, tested positive for many substances. 
Because a period of amphetamine use will proba-
bly end if problems arise (admissions to hospitals 
and deaths), and the user at the same time tries to 
deal with these problems by taking depressants 
such as benzodiazepines or methadone, some 
analyses (hospital data or autopsy cases) may 
exaggerate the use of different drugs. 
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Figure 18: The number of seizures (both analyzed in 
laboratory and not analyzed in laboratory) that have 
been confirmed as containing amphetamine or meth-
amphetamine by laboratory analyses 1994–2008.
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Figure 17: Findings of amphetamine and meth-
amphetamine in autopsies where forensic toxico-
logical analysis have been performed. In numbers 
2000–2008.
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Table 17: Number of forensic toxicological analyses in connection with autopsies 2000 to 2008, the number of 
cases of suspicion of driving under the influence of other substances than alcohol 2000 to 2008, the number of 
cases from the criminal justice system analysed at NIPH 2000 to 2008, and seizures made by the police and 
customs authorities 1994 to 2008.
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Forensic 
autopsies 
with toxi-
cological 
screening
1,855 1,741 1,768 1,640 1,645 1,581 1,579 1,544 1,659
Driving 
under the 
influence
3,833 4,314 5,116 4,379 4,020 4,050 4,213 4,296 4,474
Criminal 
justice
20,866 22,561 23,601 27,061 23,403 21,572 22,094 24,302 25,702
Seizures 8,171 11,357 11,734 14,812 17,828 20,141 21,508 27,649 30,310 25,210 24,108 24,118 26,249 24,568 23,835
Sources: Norwegian Institute of Public Health and Kripos
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Innenfor Helsedirektoratets tilskuddsordninger 
legges det stor vekt på at tiltakene skal evalueres 
og det bevilges særskilte midler til evaluering av 
tiltak. Målet er at dette skal bidra til å styrke kva-
liteten og støtte kunnskapsbaserte strategier og 
tiltak med kontinuitet og lokal forankring. 
Narkotikabruk blant unge
Den seneste ESPAD undersøkelsen blant 15-16 år 
gamle skoleelever ble gjennomført i 2007. Tallene 
viser stabilitet og til dels en nedgang sammenlig-
net med tidligere års undersøkelser.  Nedgangen 
er mest markert i bruken av cannabis. I 2007 op-
pga rundt seks prosent å ha brukt cannabis noen 
gang, mens de tilsvarende andelene for 2003 var 
ni prosent, i 1999 12 prosent. Bruk siste 30 dager 
viser derimot ingen tydelige endringer og har vært 
to-tre prosent i de to siste undersøkelsene. Ned-
gangen i cannabisbruk speiler også tendensen i 
Europa sett under ett. 
For andre illegale stoffer enn cannabis har det 
kun vært mindre endringer i livstidsprevalensen 
blant unge under 20 år. Derimot har det vært en 
tredobling i andelen unge voksne 21-30 år som 
har brukt kokain noen gang, fra tre prosent i 
1998 til ni prosent i 2006. Andelen som har brukt 
amfetamin noen gang, har økt fra fem til ti pro-
sent i samme periode. Men andelen unge voksne 
som har brukt amfetamin eller kokain siste seks 
måneder holder seg stabilt rundt to prosent. 
Det synes å være en klar sammenheng mellom 
bruk av cannabis og sentralstimulerende midler 
både blant ungdom og unge voksne. Med økende 
antall ganger brukt cannabis var det en klar øk-
ning i andelen som også hadde brukt sentralsti-
mulerende stoffer. Av de som har brukt cannabis 
mer enn 51 ganger hadde flertallet også prøvd 
amfetamin eller kokain. De aller fleste som opp-
ga å ha brukt sentralstimulerende stoffer hadde 
tidligere brukt hasj.
Hovedrapporten – Del A
Nasjonal politikk og sammenhenger 
Stortinget vedtok 15. juni 2009 å gjøre den 
midlertidige sprøyteromsloven permanent. 
Sprøyteromsordningen skal være et supplement i 
en helhetlig tiltakskjede for de som har store 
helsemessige problemer og vanskeligheter med å 
komme seg ut av sitt narkotikamisbruk. Den en-
kelte kommune kan selv ut fra lokale behov velge 
om den ønsker å etablere en sprøyteromsordn-
ing. Lovendringene med tilhørende forskrift trer 
i kraft 17. desember 2009.
Regjeringens opptrappingsplan for rusmiddel-
feltet ble lagt fram for Stortinget i oktober 2007. 
Den omfatter mål og tiltak innen forebygging, 
behandling og rehabilitering, og legger opp til en 
gradvis økonomisk opptrapping fram mot 2010. 
Helsedirektoratet har ansvar for å implementere 
og gjennomføre store deler av rusmiddelpolitik-
ken. Direktoratet skal videre sørge for oversikt 
over rusmiddelsituasjonen på regionalt og lokalt 
nivå, tildele tilskudd til frivillige organisasjoner 
på rusmiddelområdet og utgi en årlig statusrap-
port. 
Ifølge Helsedirektoratet var 115 av planens 147 
tiltak igangsatt ved utgangen av 2008. Mange av 
tiltakene evalueres uavhengig av hverandre, og 
det planlegges en samlet gjennomgang av erfa-
ringene med planen.
I alt er det ansatt 19 rusrådgivere fordelt på de 18 
fylkesmannsembetene. Rusrådgiverne skal bidra 
til iverksetting og gjennomføring av opptrap-
pingsplanen i kommunene. Det er i gang et treå-
rig forsøk med koordinerende tillitspersoner i 30 
utvalgte kommuner. Formålet med tillitsperso-
ner er å bidra til at rusmiddelmisbrukere får et 
mer helhetlig og individuelt tilpasset tjenestetil-
bud, som bidrar til økt sosial inkludering og livs-
mestring.
Summary in Norwegian
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Blant problembrukere
Antall sprøytemisbrukere i 2007 ble anslått til 
være mellom 8 600 og 12600. Estimatet omfatter 
all injeksjonsbruk. Heroin er det mest vanligste 
stoffet som injiseres, men amfetamin forekom-
mer også.
I en ny undersøkelse som dekker perioden 2000 
til 2008 er det blitt beregnet hvor mange perso-
ner som har brukt heroin i Norge, inklusive de 
som bare røykte stoffet. For å kunne beregne det 
totale forbruket ble brukerne delt inn etter hyp-
pighet og bruksmåte. Basert på ulike metoder ble 
det anslått at mellom 6 600 og 12 300 brukte he-
roin regelmessig i 2008, en betydelig nedgang fra 
2000 da estimatet var mellom 9 550 og 17 750. 
Behandling 
Døgnkapasiteten har vært stabil siden 2004 med 
en viss økning av plasser for avrusning og min-
dre endringer i fordelingen mellom korttids- og 
langtidsbehandling. Flere mottar poliklinisk be-
handling, og det er en betydelig økning i antall 
som mottar substitusjonsbehandling. Tall fra 
Norsk pasientregister viser en økning på nyhen-
viste til tverrfaglig spesialisert behandling med 
16 prosent fra 2007 til 2008.
Den landsomfattende klientkartleggingen for 
2008 viser at bortsett fra alkohol, som fortsatt ut-
gjør nær halvparten av registreringene ved inn-
tak i behandlings- og omsorgstiltak, er heroin 
oftest oppgitt som mest brukte rusmiddel (18 %). 
Andelen som oppgir heroin viser imidlertid en 
sterkt fallende tendens. I 2006 var den 24 pro-
sent, i begynnelsen av 2000-tallet lå den på rundt 
35 prosent.  Forskjellene mellom kjønnene har 
flatet ut, andelen kvinner som oppga heroin som 
mest brukte rusmiddel var langt høyere for noen 
år siden. Cannabis og sentralstimulende stoffer 
som mest brukte rusmiddel viser ingen endring i 
andeler fra 2006 til 2008. Kjønnsforskjellene er 
også stabilt små for begge stoffgruppene.
Helseforhold og konsekvenser 
HIV-insidensen blant injiserende misbrukere i 
gruppen holder seg stabilt lav med ca 10-15 
meldte tilfeller årlig. Årsaken til dette er ikke en-
tydig, men høy testaktivitet, stor åpenhet om 
HIV-status internt i misbrukermiljøene kombin-
ert med sterk smittefrykt og selvjustis i miljøet, 
antas å spille en viktig rolle.
Både tallene fra Statistisk sentralbyrå og Kripos 
indikerer at det har vært stabilitet i antall narko-
tikarelaterte dødsfall de siste 5-6 årene. Antallet 
overdosedødsfall årlig er likevel fortsatt høye. 
Selv om antall klienter i legemiddelasssistert re-
habilitering har økt sterkt i samme periode, har 
dette ikke ført til en markert nedgang i antallet 
døde.
Narkotikakriminalitet 
I 2008 ble det anmeldt 37 531 narkotikalovbrudd, 
ett av de laveste tallene de siste ti årene. Nedgan-
gen fra 2007 var noe større for narkotikalovbrud-
dene som reguleres av legemiddelloven enn for de 
mer alvorlige narkotikaforbrytelsene etter 
straffeloven. I 2007, som er det hittil siste året hvor 
slik informasjon er tilgjengelig, ble det gitt 14430 
domfellelser for narkotikaforbrytelser. Kun 1 220 
dommer resulterte i ubetinget fengsel. Antall 
dommer og overføringer som alternativ til fengsel 
viste en markert økning i 2008 sammenlignet med 
tidligere år. 
Narkotikamarkedet, tilgjengelighet og 
innførsel 
For første gang er det gjort beregninger av hvor 
stort forbruket av heroin sannsynligvis er i Norge 
i løpet av et år. I følge undersøkelsen ble mengde 
heroin brukt i 2006 anslått til å utgjøre om lag 1 
445 kilo, mens forbruket i årene 2000-2002 ble 
anslått å være i overkant av 2 000 kilo. Nedgan-
gen skyldes i all hovedsak en reduksjon i antall 
problembrukere. Estimatet for 2006 antas også å 
kunne gjelde for 2007 og 2008. 
Heroin som omsettes i Norge kommer hovedsa-
kelig fra Afghanistan via Tyrkia med to nordlige 
ruter over Bulgaria/Romania – Ukraina/Russ-
land, så Polen /Litauen. To sørlige ruter går gjen-
nom Hellas/Balkan til Nederland/Tyskland.
I følge Tollvesenet stammer mesteparten av am-
fetamin/metamfetaminet på det norske marke-
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det fra illegale laboratorier i Nederland, Polen og 
Litauen. Litauiske kriminelle har over flere år 
hatt en dominerende rolle som leverandør av 
syntetisk narkotika til Norge, og andelen av be-
slaglagt metafetamin fra Litauen er økende. Li-
kevel kommer i dag de største mengdene med 
amfetamin som beslaglegges fra Nederland og 
Polen. Hovedrutene går gjennom Tyskland og 
Danmark via Sverige.
Cannabis som beslaglegges i Norge kommer ho-
vedsakelig fra Marokko via Nederland, mens ko-
kain kommer som tidligere fra Sør Amerika til 
Afrika og Spania og videre til Nederland og 
Tyskland, og deretter opp gjennom Danmark til 
Norge.
Beslag 
For perioden 2000-2008 har SIRUS beregnet poli-
tiets og tollvesenets samlete beslag av mengde 
heroin til å utgjøre i gjennomsnitt bare fire prosent 
av det antatte totalforbruket av heroin i Norge per 
år. Den høyeste andel beslag var i 2004, åtte 
prosent av årsforbruket, mens den laveste andelen 
var i 2007, noe under tre prosent.
I 2008 ble det registrert 19 619 narkotikasaker og 
23 835 narkotikabeslag. På landsbasis er dette en 
nedgang fra 2007 på henholdsvis 4 og 3 prosent. 
Det er imidlertid store innbyrdes forskjeller mel-
lom de ulike stofftypene. Mens det i 2008 bare 
var små endringer i antall beslag av de mest van-
lige stoffene, var endringene i beslaglagt mengde 
betydelige. 
Mens beslagene av heroin i 2007 var kun 8 kg, 
ble det i 2008 på nytt gjort en rekke middels store 
beslag, til sammen 55.2 kg. Heroin utgjorde i 
2008 bare fem prosent av det totale antallet nar-
kotikabeslag i Norge. Til sammenlikning var an-
delen i 1998 så stor som 20 prosent.
Det største amfetaminbeslaget noen gang i Nor-
ge ble gjort i 2008, hele 112.3 kg. Basert på antall 
beslag og verifiserte analyser, økte innslaget med 
metamfetamin i forhold til amfetamin igjen be-
tydelig.
Beslaglagt mengde cannabis var i 2008 1 732 kg 
og fordelte seg på om lag 71 prosent hasj, ni pro-
sent marihuana og 20 prosent cannabisplanter. 
Ett beslag av hasj på 401 kg dominerte. Også før-
ste halvår 2008 ble det avdekket mange, til dels 
store «cannabisplantasjer». 
I 2008 ble det beslaglagt mindre mengder kokain 
enn i 2007. Kokain ble beslaglagt i 26 av landets 
27 politidistrikter, men det er relativt store end-
ringer mellom politidistriktene. I Oslo er ned-
gangen i antall beslag på 17 prosent, mens det for 
Bergen er registrert en økning på 63 prosent.
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Spesialtema – Del B
Cannabismarkedet
Fra politihold hevdes det ofte at cannabismarke-
det har vært dominert av noen få store aktører 
som har drevet i flere tiår. Koblingene til etablerte 
organiserte kriminelle miljøer som driver med 
flere former for lovbrudd er vel kjent.
Markedet synes å være svært fleksibelt og man 
finner flere ganske ulike miljøer knyttet opp mot 
det. Omsetningen på gatenivå har en relativt god 
oversikt over. Smuglere og kurerer har man også 
relativt god kunnskap om. Såkalte bakmenn og 
de som er grossister vet man derimot lite om. 
Spørsmålet er selvsagt hvorvidt man har noen 
tydelige bakmenn. Mye tyder på at det er få ledd 
mellom innførsel og direkte salg av hasj til bru-
ker. Ut fra beregninger av pris kan det se ut som 
selgere kjøper av personer som har kjøpt fra im-
portørene eller at det er ett ledd til.
Fleksibiliteten i innførselen av cannabis gjør at 
det er et marked åpent for mange. Det er tilpas-
ningsdyktig og vil derfor i liten grad påvirkes av 
at politi eller toll makter å ta en eller flere av de 
større aktørene.  Det er interessant å merke seg at 
smugling av hasj i flere tilfeller kombineres med 
smugling av piller, amfetamin og ecstasy. På den 
annen side synes det å være nesten vanntette 
skott mellom de som driver med heroin og hasj. 
Det er også meget sjelden at spritsmuglere har 
noe med hasj å gjøre.  
Cannabismarkedet knyttes ofte opp mot særskilte 
etniske grupper. Det antas at marokkanerne har 
fått en sentral rolle i flere land i Europa. I Norge 
synes innførsel og distribusjon stort sett å være en 
multietnisk virksomhet. Ofte kan en se smugler-
lag sammensatt av personer med både norsk, asia-
tisk og afrikansk bakgrunn. Omsetningen på ga-
teplan har de senere år langt på vei blitt dominert 
av grupper med innvandrerbakgrunn. 
Problembruk av amfetamin  
og metamfetamin
Hovedfunnene i datagrunnlaget peker mot at det 
har vært en økning i bruken av amfetaminer i 
Norge i mange år og at denne økningen har vært 
størst for metamfetamin. Slik sett står under-
søkelsen noe i kontrast til tidligere rapporter som 
påpeker lite bruk av metamfetamin i vår del av 
Europa, mens den bekrefter tidligere rapporter fra 
EMCDDA som påpeker at Norge er det landene i 
Europa med de mengdemessig største og i antall 
fleste beslagene, og hvor problemene knyttet til 
metamfetamin også kan være betydelige.
Det mest oppsiktsvekkende funnet i den forelig-
gende undersøkelsen er at mesteparten av bru-
ken av amfetaminer nå synes å være metamfeta-
min. Økningen i andel har vært en lineær trend 
over mange år i alle de foreliggende datakildene. 
For beslag synes det som om 2009 vil være det 
året da antall beslag av metamfetamin vil passe-
rer amfetamin.
Trolig har denne trenden mer med tilbud å gjøre. 
I takt med liberaliseringen av grensekontrollen i 
Europa har man fått nye mønstre for handel med 
narkotika. Det er grunn til å tro at den viktigste 
forklaringen på skiftet fra amfetamin til metam-
fetamin som dominerende substans i Norge skyl-
des nye produsenter og importører i markedet, 
muligens produksjon i de baltiske landene.
Kombinasjonen av at brukere ikke kjenner til om 
det er amfetamin eller metamfetamin de inntar, 
at bruken av amfetaminer er økende, at metam-
fetamin nå etter hvert er det dominerende amfe-
taminet på market i Norge innebærer en klar fare 
for at vi vil se flere negative følger av bruk i Nor-
ge enn i mange andre land. Tilgjengelige data fra 
veitrafikken og psykiatrien er to eksempler som 
peker i den retningen. 
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